University of Texas at Tyler

Scholar Works at UT Tyler
Nursing Theses and Dissertations

School of Nursing

Summer 8-14-2017

META-REGRESSION: PROGNOSTIC
MODELS AS OBJECTIVE PREDICTORS OF
MORTALITY AMONG ICU CANCER
PATIENTS
Sheila Donnell
University of Texas at Tyler

Follow this and additional works at: https://scholarworks.uttyler.edu/nursing_grad
Part of the Critical Care Commons, Critical Care Nursing Commons, and the Oncology
Commons
Recommended Citation
Donnell, Sheila, "META-REGRESSION: PROGNOSTIC MODELS AS OBJECTIVE PREDICTORS OF MORTALITY AMONG
ICU CANCER PATIENTS" (2017). Nursing Theses and Dissertations. Paper 75.
http://hdl.handle.net/10950/590

This Dissertation is brought to you for free and open access by the School
of Nursing at Scholar Works at UT Tyler. It has been accepted for inclusion
in Nursing Theses and Dissertations by an authorized administrator of
Scholar Works at UT Tyler. For more information, please contact
tbianchi@uttyler.edu.

META-REGRESSION: PROGNOSTIC MODELS AS OBJECTIVE PREDICTORS OF
MORTALITY AMONG ICU CANCER PATIENTS

by

SHEILA K. DONNELL

A dissertation submitted in partial fulfillment
of the requirements for the degree of
Doctor of Philosophy
Department of Nursing
Barbara K. Haas, Ph.D., Committee Chair
College of Nursing & Health Sciences

The University of Texas at Tyler
July 2017

The University of Texas at Tyler
Tyler, Texas
This is to certify that the Doctoral Dissertation of
SHEILA KATHRYN DONNELL
has been approved for the dissertation requirement on
July 17, 2017
for the degree of Doctor of Philosophy in Nursing

Approvals:
__________________________________
Dissertation Chair: Barbara K. Haas, Ph.D.
__________________________________
Member: Yong Tai Wang, Ph.D.
__________________________________
Member: Danice Greer, Ph.D.
__________________________________
Member: Gloria Duke, Ph.D.
__________________________________
Executive Director, School of Nursing
__________________________________
Dean, College of Nursing and Health Sciences

Copyright © 2017 by Sheila Donnell
All rights reserved.

Dedication
This body of work is dedicated to the beautiful muse in my life, Kennedy N. Donnell.
Thank you for the beauty of inspiration.

Acknowledgements
Parents, family members, teachers, peers, friends and strangers are like nutrients
sowed into the ground and PhD candidates are the soil. Each nutrient is distinct, serving a
unique role to produce healthy soil. The blending of nutrients makes it difficult to
decipher the specific meaning of individual encounters and influences. Nevertheless, I am
healthy soil due to the nutrient value of important elements in my life. To the nutrients in
my life, I say, “thank you.”
Water, sunlight, and wind are special people whom represent those individuals
most invested in the success of a PhD candidate. As a PhD candidate, I say to my water
and my sunlight, “because of you, I am”. In memory of my mother, your rain forced me
to grow good things. In honor of my father, your sunlight motivated me to cultivate
important things. I declare to my daughter, your wind reminded me to breathe in oxygen.
Oftentimes, ideal relationships germinate from kinship. For this reason, my cousin was
able to show me how to pull it altogether (nutrients, sunlight, water, and oxygen) so that I
am able to produce great things.
To the University of Texas at Tyler, School of Nursing staff, I am deeply grateful
for the opportunity to see a dream finally realized. The many experiences and
relationships will have a life-long impact on my contribution to the nursing profession. I
am thankful for the time and contribution of each committee member. Special gratitude is
extended toward Dr. Barbara Haas for her mentorship along this important milestone. Dr.
Duke reminded me of the importance to always raise the bar of expectation. I truly
appreciate Dr. Wang and Dr. Greer’s expertise and validation of this body of work.

Table of Contents
List of Tables ..................................................................................................................... ix
List of Figures ..................................................................................................................... x
Abstract .............................................................................................................................. xi
Chapter 1 ............................................................................................................................. 1
Introduction ............................................................................................................... 1
Purpose Statement ..................................................................................................... 3
Background .............................................................................................................. 4
Prognostic Models .......................................................................................... 4
Cancer Patients in the ICU .............................................................................. 6
Significance............................................................................................................... 8
Patient Family Centered Experience ............................................................... 8
Prognosis in the Nursing Process .................................................................. 10
Theoretical Underpinnings...................................................................................... 12
Homeostasis ................................................................................................. 13
Bayes Reasoning .......................................................................................... 15
Objectivity.................................................................................................... 16
Objectivity in the Nursing Process .................................................... 17
Research Questions ................................................................................................ 18
Definition of Terms................................................................................................ 19
Summary ................................................................................................................ 21
Chapter 2 ........................................................................................................................... 24

i

Review of the Literature ................................................................................................... 24
Prognosis ................................................................................................................. 25
Prognostic Models .................................................................................................. 26
APACHE II in the Literature .................................................................................. 31
SAPS II in the Literature......................................................................................... 34
SOFA in the Literature............................................................................................ 38
Bedside Context of Prognostic Models................................................................... 40
Summary ................................................................................................................. 41
Chapter 3 ........................................................................................................................... 43
Methods............................................................................................................................. 43
Research Questions ........................................................................................................... 43
Design ..................................................................................................................... 43
Procedure ...................................................................................................... 44
Data Extraction and Collection ..................................................................... 45
Statistical Analysis ........................................................................................ 48
To Test Heterogeneity................................................................................... 48
Chapter 4 ........................................................................................................................... 51
Results… ................................................................................................................. 51
Description of Sample................................................................................... 51
Model Predictions in the Sample .................................................................. 53
Model Performance Statistics ....................................................................... 54
Heterogeneity Testing ................................................................................... 55

ii

Independent Predictors of Mortality ....................................................................... 64
Chapter 5 ........................................................................................................................... 66
Summary ........................................................................................................................... 66
Discussion ......................................................................................................................... 67
Sample..................................................................................................................... 67
Primary Study Aim ................................................................................................. 68
Secondary Study Aim ............................................................................................. 69
Conclusion ........................................................................................................................ 70
Nursing Implications ............................................................................................... 71
References ......................................................................................................................... 73
Bibliography ................................................................................................................... 110
Appendix A. Combination ICU Mortality model ........................................................... 118
Appendix B. Acute Physiology and Chronic Health Evaluation II model. .................... 120
Appendix C. Simplified Acute Physiology Score II model. ........................................... 121
Appendix D. Sequential Organ Failure Assessment model ............................................ 123
Appendix E. Overall Predictive Performances of Prognostic Models. ........................... 124
Appendix F. Characteristics of Validated Studies. ......................................................... 128
Appendix G. Curriculum Vitae.. ..................................................................................... 131

iii

List of Tables
Table 1: Classifying Predictive Accuracy of a Prognostic Test ....................................... 31
Table 2. Acute Physiology and Chronic Health Evaluation II mortality Scores .............. 33
Table 3. Simplified Acute Physiology II Scores ............................................................... 36
Table 4. Sequential Organ Failure Assessment Scores ..................................................... 40
Table 5. Test of Heterogeneity.......................................................................................... 60
Table 6. Summary AUC with Random-Effects Model ................................................... 117

iv

List of Figures
Figure 1. Prognostic Framework....................................................................................... 14
Figure 2. PRISMA Flow Diagram .................................................................................... 48
Figure 3. CHARMS Key Items Checklist......................................................................... 31
Figure 4. Flow Chart of Literature Selection .................................................................... 55
Figure 5. APACHE II Cohort: Pooled Weighted Studies ................................................. 62
Figure 6. SAPS II Cohort: Pooled Weighted Studies ....................................................... 63
Figure 7. SOFA Cohort: Pooled Weighted Studies .......................................................... 64
Figure 8. APACHE II Funnel Plot Asymmetry Test ........................................................ 67
Figure 9. SAPS II Funnel Plot Asymmetry Test .............................................................. 68
Figure 10. SOFA Funnel Plot Asymmetry Test ............................................................... 69

v

Abstract

META-REGRESSION: PROGNOSTIC MODELS AS OBJECTIVE PREDICTORS OF
MORTALITY AMONG ICU CANCER PATIENTS
Sheila Donnell
Dissertation Chair: Barbara K. Haas, Ph.D.
The University of Texas at Tyler
July 2017

Cancer patients admitted to the intensive care unit (ICU) may be experiencing
complications of disease or treatment-related effects. While acute complications related
to disease and/or its therapeutic management vary in severity, the approach to ICUcentered care is complicated by actual versus perceived risks of poor outcomes.
Prognostic models that inform clinical judgment of nurses and physicians may prove
helpful in this population. The Acute Physiology and Chronic Health Evaluation II
(APACHE II), Simplified Acute Physiology Score II (SAPS II) and Sequential Organ
Failure Assessment (SOFA) are ICU-based models predicting 30-day mortality among
the general ICU population. Although studies have been published on use of each model,
prognostic accuracy for predicting 30-day, all-cause ICU mortality in the cancer
population has yielded mixed results.
The purpose of this study was to determine which prognostic model demonstrated
greatest prognostic accuracy among oncology patients. Framed within a derived
Prognostic Framework, a meta-analysis of prospective and retrospective cohort studies
using literature searches of CINAHL, Cochrane, PubMed and Web of Science databases
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spanning 2000 to 2017 timeframe was performed. Meta-regression with a random-effects
model was used to summarize area under the receiver-operating characteristic curves
(AUCs) to estimate overall predictive accuracy for the APACHE II, SAPS II, and SOFA.
After comparing performances, APACHE II demonstrated greatest predictive accuracy.
Keywords: Prognostic models, intensive care unit, cancer, meta-analysis, metaregression
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Chapter 1
Introduction
Critically ill oncology patients admitted to the ICU are a vulnerable at- risk population
for clinical bias towards perceived poor prognoses (Bird et al., 2012; Kopterides et al., 2011;
Neville et al., 2015). Negative preconceived notions about the clinical response of oncology
patients to aggressive medical management in the critical care environment are reflective of
biases and misunderstandings related to cancer diagnoses, traditional treatment methods, and
past approaches to symptom management (Cruz, Camalionte, & Caruso, 2015; Louie et al.,
2013; Mohammed & Peter, 2009). Perception of prognosis is often demarcated between
specialists (oncology experts versus critical care professionals) sharing ICU patients rather than
full engagement and thorough information exchange across disciplines (Daly et al., 2016).
Information and knowledge gaps compromise clinical perceptions, leaving critically ill cancer
patients vulnerable to subjective opinions regarding patients’ prognoses of cancer patients (Frost,
Cook, Heyland, & Fowler, 2011; Mohan, Alexander, Garrigues, Arnold, & Barnato, 2010; Uy,
White, Mohan, Arnold, & Barnato, 2013; Visser, Deliens, & Houttekier, 2014).
The current state of cancer treatment and improved short-term survival outcomes in acute
care settings are the catalyst for ensuring objective modes of determining prognoses in the
oncology population are applied at the bedside. The 21st century ushered in technological and
biomedical advancements in oncology that date back to the signing of the National Cancer Act
(NCA) of 1971. Through its legislative edicts, major investments in cancer research have led to
historic successes in the areas of improved chemotherapies, biotherapeutic developments,
imaging technology, and enhanced side effect management (Conway, Carragher, & Timpson,
2014; Gambhir, 2002; Ozols et al., 2007; Tiwari & Roy, 2012; Vogelzang et al., 2012;
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Weissleder, 2006; Wingo et al., 2003). Some patients diagnosed with cancer can now expect
favorable prognoses amid serious disease and treatment-related complications requiring intensive
care management (Schellongowski et al., 2004; Torres et al., 2016).
Investigation into improving the accuracy of prognostic information is warranted to
reduce the subjective nature of perceived poor outcomes at the bedside (Hall, 2017). Relying
solely on subjective notions to discriminate between favorable and unfavorable prognoses early
into the admission process have not proven to be precise among critical care nurses and
physicians (Detsky et al., 2017; Hall, 2017). Outcomes from studies examining predictive
prognostic accuracy and concordance between critical care nurses and physicians revealed low
accuracy rates and discordance between disciplines (Detsky et al., 2017; Neville et al., 2015).
Acquisition of models that accurately discriminate prognosis remain promising. When applied
appropriately, prognostic models can contribute important analytical information to guide the
clinical care of patients (Detsky et al., 2017; Liu et al., 2015; Sawicka, Owczuk, Wujtewicz, &
Wujtewicz, 2014).
Several validated prognostic models (vPMs) are readily available for use in the ICU to
predict short-term mortality risk (i.e., 30-day ICU stay). Three of the most widely used vPMs in
the critical care environment are the Acute Physiology and Chronic Health Evaluation II
(APACHE II), Simplified Acute Physiology Score II (SAPS II) and Sequential Organ Failure
Assessment (SOFA) (Vincent & Moreno, 2010). The vPMs may be utilized to provide
information for determining acuity of care among critically ill patients, make nurse-patient
assignments, and support patient-family decisions about care. To-date, APACHE II, SAPS II,
and SOFA perform well when discriminating between likely survivors and non-survivors in
general ICU patient populations (Horster et al., 2012; Keegan, & Soares, 2016; Vincent &
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Moreno, 2010). A knowledge gap exists about how well vPMs perform in critically ill ICU
cancer sub-populations (Sawicka, Owczuk, Wujtewicz, & Wujtewicz, 2014). Exploring the
performances of APACHE II, SAPS II, and SOFA among critically ill ICU cancer patients is an
opportunity to determine utility of these tools to critical care staff at the bedside.
Purpose Statement
Performances of APACHE II, SAPS II, and SOFA emerged as objective measures for
obtaining a prognosis among critically ill ICU patients. Good performance has been established
for each vPM in general ICU populations, but overall performances in an ICU sub-population,
such as critically ill cancer patients, have not been established. The primary aim of this study was
to identify the vPM demonstrating greatest prognostic accuracy in the critically ill adult
oncology ICU sub-population. To address the primary aim, meta-analysis was performed to test
pooled results gathered from the best available research.
The APACHE II, SAPS II, and SOFA models were selected based on established
validity, objectivity, wide use, and broad acceptance in the critical care medicine domain
(Vincent & Moreno, 2010). Each model had been studied in several adult general ICU
populations and ICU sub-populations resulting in the assumption that study-level data would be
available in the literature. For that reason, measuring the overall performances of APACHE II,
SAPS II, and SOFA models using a structured, systematic approach to aggregate the findings of
published literature was determined to be the best approach to meeting the study purpose.
Prognostic model performance research commonly includes univariate analysis of
variables (e.g., covariates) being tested for a relationship to ICU mortality. Covariates are
prognostic indices not captured in the model of interest but determined to be independent
outcome determinants of 30-day ICU mortality and/or influence the predictive accuracy of vPMs
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(Ramsey et al., 2008). Each vPM aggregates several, though slightly different, physiological
variables to determine mortality risk. Examples of physiological variables not included in any
vPM algorithms but well-established as indicators of cancer-related mortality outcomes include
the patient “performance status” score at the time of ICU admission, serum albumin level, and
hydration status (Li et al., 2017; Nwosu et al., 2016; Wolf et al., 2016). Therefore, the secondary
aim was to describe covariates reported as independent predictors of 30-day ICU mortality.
Background
The topic of vPM application is broad and discussion of significance in the oncology
population is multifaceted. When considering the complexity of cancer patients admitted to the
ICU, advances in life-sustaining technology, and changing societal expectations for recovery,
accurate prognostication in the ICU becomes emotionally charged and challenging for critical
care staff (McDermid & Bagshaw, 2009). Despite the heterogeneity of oncology patients
admitted to the ICU, biases against aggressively treating critically ill cancer patients, in general,
persist in this setting and creates ethical concerns. Conversely, patients and/or families may
request aggressive measures even when care is futile. It is within this context that the predictive
accuracy of vPMs has a distinct role to play in the relationship between 30-day intensive care
mortality and cancer-specific prognosis in the ICU.
Prognostic Models
General validated prognostic models (vPMs) are tools that offer a systemized way of
aggregating physiological variables known to be predictors of survival outcomes in the ICU. For
the purpose of conducting a meta-analysis, this study was limited to three vPMs: APACHE II,
SAPS II, and SOFA. As generic prognostic systems, the information yielded by each vPM is
used to establish 30-day ICU mortality risk among critically ill patient groups (Yu et al., 2014).
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Mortality risk is quantified using the values of a set of physiological variables routinely observed
and measured in the ICU by critical care nursing and physician staff. Each physiological variable
used in a given vPM to generate a prognosis, is measured via ICU-based hemodynamic
monitoring apparatuses and laboratory specimens (e.g., serum calcium and potassium). These
same variables are reported regularly in critical care nursing documentation; thus, simplifying
the steps needed to generate a prognosis at the bedside.
Every vPM performs statistical calculations to produce a raw severity-of-illness (SOI)
score and corresponding estimated mortality reported in the form of a percentage. Although the
bedside nurse collects and documents the information needed in the medical record, either
critical care nurses (CCNs) or intensivists enter the data into a vPM calculator for a mortality
probability estimate. A physician then interprets the SOI score and percentage by translating
these integers into clinical meaningful information. The information gathering and sharing
process among the nurse-physician teams makes providing a prognosis to patients/families a
collaborative process between CCNs and intensivists.
The calculation (SOI score and percentage of estimated mortality risk) is translated into
terms most appropriate for patient/family levels of education and comprehension. As a
stipulation, these systems were validated based on measurements obtained within the first 24hours of admission for their hypothesized predictive accuracy and must be applied in the same
manner. As a result, the worst values observed within the first 24 hours are used for baseline
assessments of patient 30-day survival chances as well as determining baseline prognoses (i.e.,
favorable versus unfavorable).
The function of vPM calculations resulting in SOI scores are based on vital sign
measurements and laboratory values of selected physiological variables specified per prognostic
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system to predict mortality risk. Values of physiological variables (e.g., serum electrolytes, white
blood cells, arterial blood gases, Glasgow coma scale) included in each vPM are weighted
according to their known relative impact on 30-day ICU mortality (Vincent & Moreno, 2010).
Although the physiological variables, along with importance of their corresponding values,
reasonably vary from one prognostic scoring system to the next, each model combines their
values for analysis using logistic regression techniques and equations (Vincent & Moreno, 2010).
Specifically, multiple logistic regression is used in each vPM to provide the probability of 30day ICU mortality (Vincent & Moreno, 2010). As a result, vPMs are established objective tools
capable of stratifying patients into groups in relation to benefit/non-benefit of aggressive care
measures when admitted into the ICU (Leung, McArdle, & Wong, 2011).
Cancer Patients in the ICU
Advances in the delivery of care outside of oncology specialization and the use of lifesaving strategies in the acute care setting contribute significantly to the increase in short-term
survival outcomes in the ICU. The critical care environment is where specialized knowledge and
the actions of non-oncology nurse-physician teams make use of advancements in life-saving
strategies that greatly impact 30-day mortality for critically ill persons. This setting was of
interest in this study because the number of patients with hematological malignancies and solid
tumors admitted to this environment has increased (Torres et al., 2016). Past studies report
improved survival outcomes in several subsets of this patient population while no differences in
survival outcomes among critically ill cancer patients were observed when compared to general
critical care patient mixes (Benoit et al., 2003; Torres et al., 2016).
Similar to the general ICU population, patients admitted to the ICU with a cancer
diagnosis have situational needs. For example, treatment-related effects due to anti-cancer agents
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(e.g., sepsis, renal toxicity, coagulopathy) can be very serious yet reversible when timely,
thoughtful management approaches are delivered in intensive care settings (Parakh et al., 2014).
Prognosis related to severe insult to health because of treatment is distinctively different from a
cancer prognosis; rather, prospects of recovery are associated with the severity of
complication(s) from treatment and how adverse events can be managed best in intensive care
environments. In addition, certain cancer types are very aggressive at the time of diagnosis and
respond well to treatment, but carry a poor prognosis when left untreated. For example, a disease
such as acute promyelocytic leukemia is very aggressive and deadly but “curable”. However, it
requires appropriate drug combinations administered to a patient under close monitoring
conditions most conducive to ICU care practices (Rowland et al., 2013; Walker & HeldWarmkessler, 2010).
Some cancer treatments, such as immunotherapy administered for malignant melanoma
requires meticulous nurse monitoring due to life threatening side effects (Yu & Si, 2017). The
nurse-to-patient ratio and nursing skill levels unique to the ICU environment are supportive of
rigorous patient care needs. Therefore, the critical care nursing staff is readily available to
identify serious side effects associated with immunotherapy and facilitate timely care. In this
situation, the cancer prognosis is poor due to aggressivenessof disease, while the intent of
successful treatment is “cure”. Because the physiological demand on the patient is great, ability
to tolerate therapy is very challenging, and individual response varies; therefore, improved
prognosis is not guaranteed with this type of treatment (Lefebvre et al., 2017).
There are case scenarios more clearly indicative of unfavorable prognosis such as cancer
patients with disease states that are terminal. Terminal illness and poor prognosis are clearly
established when cancer is no longer responding to available treatments and life-sustaining
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strategies in the ICU are ineffective. Physiological processes are overwhelmed, health continues
to decline, and death is imminent with absolute certainty. In this case, a patient receives a poor
prognosis most befitting of a deteriorating condition and continued efforts to sustain life are
reasonably futile.
On the other hand, there are patients with a cancer diagnosis admitted post-operatively
with complications related to surgery who recover well. In this scenario, both the cancer
prognosis and 30-day ICU prognosis can be favorable. Moreover, if a post-op patient with cancer
suffers from a life threatening condition unrelated to the malignancy, it is the 30-day ICU
prognosis that is unfavorable. The impetus for exploring the different needs of cancer patients in
the ICU is to establish that prognoses ought to be tailored around the immediate acute
physiological needs and ICU-specific diagnoses of patients, rather than conditioned beliefs about
delivering care perceived to be futile. Nevertheless, proficient, high acuity care delivered by
nursing and medical staff in the ICU makes it the setting best suited for accessing optimum
nursing care so that critically ill cancer patients have the best chances of survival.
Significance
Patient–Family Centered Experience
Patient ICU experience and family presence at the bedside is a demanding psychological
event for both (Bolton, 2016; Nikayin et al., 2016). The experience, for patients and family
members, takes place within an environment of high-tech monitoring apparatuses, alarms, and
procedures. Studies revealed a lack of emotional support, poor communication, and failure to
explain prognosis lead to unknowns that create anxiety, psychological distress, and low
satisfaction with care for both patients and family members (Beckstrand, Lamoreaux, Luthy, &
Macintosh, 2017; Carlson et al., 2015). The significance of identifying a vPM most predictive of
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mortality outcomes in the oncology population is its use as a decision aid to offer emotional
support, communicate health status, and explain prognosis.
As decision aids, vPMs use physiological variables to assess severity-of-illness to
generate SOI scores so that these clinical factors are transformed into an “estimated-risk of
mortality” or prognosis. Using hemodynamic parameters and physiological characteristics of the
patient introduces objectivity into clinical reasoning and decision-making so that the patient and
family have practical information to make decisions. Observations of hemodynamic monitoring
and nursing care become contextual for patients and family members when staff explain how
prognosis is clinically derived from the information collected. Patient and family observers
believe conclusions are more objective when prognoses appear competently integrated into
bedside care and communication (Zier et al., 2008).
Sensitivity to staff presence by patients and families is heightened by a sense of
vulnerability and awareness of mortality. Mortality becomes deeply reflective for patients and
chance of survival is a focal point of patient/family discourse and decision-making (Hutchison et
al., 2016). Information sharing regarding prognosis and demonstrations of competence build trust
between the nurse, physician and patient-family relationship triad (Carlson et al., 2015;
Hutchison et al., 2016). According to Hutchison et al. (2016), establishing trust early is
paramount to limiting conflict that can occur during the care planning process between clinicians
and patients or their surrogate decision makers when prognoses is not fully understood.
Discordant prognostic estimates from multiple critical care staff cause patients and/or
family members to experience doubt, mistrust, and frustration (White, Engelberg, Wenrich, Lo,
& Curtis, 2010; White et al., 2016; Ziers et al., 2012). The importance of establishing vPM
performance is to have an objective tool for use as a resource to support predicting prognoses
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amidst questionable outcomes and uncertainty. A thoughtful approach by the critical care staff is
essential to managing expectations, particularly when clinical judgment is antithetical to
patient/family beliefs and desires (Ziers et al., 2012).
Moreover, communicating accurate information, such as SOI scores and estimated
mortality risk, are important to allaying concerns patients and families have at a time of critical
illness; however, it must be framed in understandable terms to be meaningful (Gigerenzer &
Edwards, 2003; White et al., 2016). The value of vPMs is best realized when the complexities of
a patient condition are translated into relatable terms by critical care staff that address knowledge
deficits and promote realistic expectations at the bedside (Gigerenzer & Edwards, 2003).
Prognosis in the Nursing Process
Admission to the ICU is associated with mortality; however, prognosis and related goals
of care are often excluded from the discussion (Hall, 2017; Turnbull et al., 2014). Nursing
research indicates CCNs have concerns about the need to take an active role in communicating
with patients, families, and physicians the significance of prognosis and setting goals of care
reflective of pragmatic approaches to its related health outcomes (Milic et al., 2015).
Establishing a prognosis early into the care process helps CCNs identify role expectations and
navigate patient/family expectations during the nursing care process.
Although the bedside nurse does not formulate a prognosis, understanding its relevance
in the care process promotes the delivery of quality care. The nursing process is central to quality
patient care and applied holistically at the bedside to ensure patient well-being. In the assessment
phase, the CCN assesses patient and family understanding of prognosis and its relation to setting
goals of care. Clinical judgment is exercised to recognize knowledge deficits associated with
patient prognosis in the diagnosis phase. Determining approaches to patient and family
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information needs are then established in the care planning phase of care. Implementation phase
involves eliciting physician perspectives on prognosis, orchestrating a family meeting with key
stakeholders, and providing emotional support.
Overall, the nursing process requires assessing and developing a care plan addressing
patient and family perspectives such as, knowledge deficits, fears, desires, and expectations
about treatments and benefits to health. Nurses are advocates ensuring patients and families
understand the care process and communication remains an open exchange for asking questions
and verbalizing concerns. A prognosis is explained within the context of individual needs,
educational level, understanding, and preferences (Parker et al., 2007). Throughout the care
process, the bedside nurse supports patients and families wanting aggressive measures employed,
despite unfavorable prognoses. The bedside nurse also supports patients with favorable
prognoses who decline certain aggressive measures that would reverse untoward health issues.
The process is circular whereby the bedside nurse re-assesses the situation, exercises clinical
judgment, modifies the plan if needed, acts on cues from patient and family, and revisits goals of
care.
Remaining respectful of preferences and values is key to maintaining quality nursing care
regardless of diverging or converging decisions in response to prognosis-related information.
Regardless of patient and family attitude towards making major health care decisions,
appropriate nursing and medical management requires careful assessment of the situation.
Turnbull et al. (2015) stated that intensivists are reluctant to discuss outcomes for critically ill
patients in the face of prognostic uncertainty and frequently do not ask surrogates about patient
values. In response, a component of nursing care is ensuring the environment is conducive to
discussions centered on prognosis so that the patient and family experience resolution of
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concerns about health-related unknowns. It is through nurse-physician shared understandings of
prognosis and clinical value that patient well-being remains at the center of decision quality.
Theoretical Underpinning
The aim of this study was to identify the vPM demonstrating the greatest prognostic
accuracy in the critically ill oncology population. The performances of APACHE II, SAPS II,
and SOFA were the primary focus. The performance of each vPM begins with measurements of
physiological variables routinely recorded in the ICU. For each model, a mathematical
computation is performed using physiological measurements to generate a raw score translated
into an estimated risk profile. The estimated risk profile is objective information used in
conjunction with clinical reasoning to communicate a prognosis to patients and surrogate
decision-makers.
To explain vPM performance at the bedside, a derived Prognostic Framework (Figure 1),
built on the underpinnings of three theories, guided the study. The borrowing of theoretical
principles collectively describe vPM function (principles of physiology and homeostasis), vPM
validity (Bayes reasoning) and vPM objectivity (Sociological Theory of Objectivity) to generate
a prognosis in this study. Principles of physiology explain how measurable physiological
variables serve as predictors of mortality. Biostatistics modeling is the logic applied to
probability testing (conditional probabilities) and estimates of mortality when physiological
predictors are aggregated using mathematical computations. Probabilities lead to estimates
converted into mortality risks to provide objective information about prognosis. All together,
each component affects the ability of the model to provide an accurate estimate of ICU mortality
and justify bedside application for individual cancer patients. That is, probability testing applied
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to human physiological responses to disease can result in objective information such as 30-day
ICU mortality risk.
Homeostasis
Each prognostic model uses physiological variables representative of well-functioning
homeostatic control in the human body. Homeostatic control or homeostasis is the degree in
which the human body maintains equilibrium in its internal environment (Rizzo, 2016).
Homeostatic process is the action of physiological mechanisms controlling human bodily
functions and monitoring conditions within organ systems. Examples of homeostasis include the
regulation of body temperature, acid-base balance, and electrolyte concentrations despite
changes in the internal and external environment. Minor fluctuations in normal blood pressure,
breathing pattern, and heart rate in response to physiological/psychological stress are signs of
well-functioning homeostasis.
Through a series of complex relationships between different human body systems,
physiological processes undergo constant adjustments through negative feedback mechanisms to
sustain physiological balance (Rizzo, 2016).Therapeutic interventions in the ICU focus on
measuring and restoring physiological balance. Issues such as critical illness, severe injury,
and/or prolonged physiological stress can decrease the adaptive capacity of homeostatic function.
Decreased adaptive function leads to inadequate homeostatic control and weakened
compensatory mechanisms resulting in increased risk of death. When homeostatic processes fail
and/or therapeutic measures are ineffective, deterioration of health continues and death is
inevitable. Accoring to the Progostic Framework, the initial step requires homeostasis data
collection and input.

13

Homeostasis

Bayesian Reasoning

Objectivity

Physiological response
to disease

Probabilities testing

Quantitative data

Input
Hemodynamic
measurements and
laboratory values

Process
Mathematical formulae and computation

Output
Estimated mortality risk

Clinical Value
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Figure 1. Prognostic Framework
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Bayesian Reasoning
Bayes reasoning is the logic that says an external reality (e.g., survival) can be predicted
when propositions (i. e., physiological variables) that capture the independent and external
reality (states of health) are in place. Bayesian theorem employs a mathematical method based
on outcomes from previous studies, prior trials, et cetera to determine the likelihood of that
observation occurring in the future (Berger, 2010; Gelman et al., 2013). It involves the use of
mathematical calculations to quantify a situation(s) such as critical illness with an uncertain
outcome(s) (e.g., 30-day ICU survivor versus non-survivor) as a part of scientific inquiry to
reveal an external reality (e.g., 30-day prognosis) (Berger, 2010; Gelman et al., 2013). By
objectively quantifying the probability of an event occurring (death), Bayesian reasoning uses
probabilistic language and computations to coincide with an independent, external reality
(observed mortality). It is a way to show correlation between a predicted reality based on
conditional probabilities and observed reality such as 30-day ICU mortality (Barton, Ethier,
Duvauferrier, & Burgun, 2017).
The concepts, mathematical language and rules of probability based in Bayesian logic
provide the framework for making objective predictions and generating objective prognoses
(Barber, 2012; Gelman et al., 2013). The aim is to reach sensible conclusions amid complicated
situations like the unpredictable yet complex needs of critically ill cancer patients. Conducting a
meta-analysis on this subject matter involved Bayesian indicators of performance: area under the
receiver operating characteristic curve (AUC); discrimination and calibration; predictive
accuracy; and objectivity (see the “Definition of Terms”) (Barbini, Cevenini, Furini, & Barbini
2014; Barton et al., 2017; Marufu et al., 2015).
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When reviewing and synthesizing the literature for meta-analysis of prognostic systems,
it is important to understand the performance of each vPM within the context of Bayesian
indicators of performance. The diagnostic performance statistic used to describe the predictive
accuracy of vPM is the AUC. This statistic represents how well a vPM uses propositional logic
to assign mortality probabilities to ICU survivors and non-survivors. Predictive performance is
assigned a probability measure (AUC values between 0 and 1) based on binary classifications
(sensitivity and specificity testing) generated by aggregating conditional variables (physiological
parameters) to objectively determine likelihood of an event occurring. In the derived Prognostic
Framework, Baysian reasoning guides the creation of an objective indicator based on the
homeostatis data from step one.
Objectivity
According to Fuchs Sociological Theory of Objectivity (1997), objectivity is realized
when outcomes measuring the same phenomenon independently, correlate strongly with each
other and across repeated measurements by several investigators. In this context, performing a
meta-analysis is the methodology for making use of a large collection of results gathered from
individual studies in order to integrate findings to gain a new objective understanding. It is a way
of viewing things dispassionately so that reproducible observations are accepted, applied and
communicated as empirical evidence.
Fuchs (1997) argues objectivity requires the scrupulous and pedantic work of stripping
away biases and prejudices, as they exist in a profane world. Through a constructivist lens,
findings that are inconclusive and/or ambiguous, detract from and hamper objectivity. The nature
of objectivity is uncovered through correspondence between accurate statements (or facts) and
the external reality. As a product of objective knowledge, a new language evolves out of
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reproducible observations; hence, the evidence obtained by means of scientific inquiry
disciplines (hold in control) subjectivity of observations in lieu of arbitrary ideas (Fuchs, 1997).
In principle, information communicated to the patient-family must be based in the best available
evidence rather than influencing factors such as mainstream social ideas, norms, beliefs,
relationships, or statuses (Fuchs, 1997).
Objectivity is both empirical and a medium of communication (Fuchs, 1997). Analyzing
the findings from a collection of studies is the conduit for establishing evidence-based
conversations about vPM function as an objective tool at the bedside and represents the third step
in the Prognostic Framework. Through the totality of the evidence, carefully made inferences
will inform and guide clinical utility. That is, objectivity sets the rules of scientific inquiry,
represents an independent reality and is a hallmark of transferrable impartiality (Fuchs, 1997).
As a result, the performances of vPMs act as conduits for objectivity, which produce objective
information for prognosis-related probabilities available to be shared. This process lay at the core
of this investigation.
Objectivity in the Nursing Process. Objectivity is an intellectual phenomenon requiring
inspecting the methods through which knowledge is formed clinically and subsequently reflected
in professional attitudes and behaviors (Engebretsen, Heggen, Wieringa, & Greenhalgh, 2016).
Constructing care that is concordant with patient’s wishes and values must start by framing
prognosis objectively using information inclusive of best and worst-case scenarios to establish
balance (Hoerger et al., 2013). Objectivity mediates subjective notions, attitudes, beliefs, and
planned actions. By providing a balanced approach using objective prognostic information,
professional biases are reduced and patients receive more than one-sided presentations of clinical
data (Hoerger et al., 2013).
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Re-conceptualizing ICU survival requires that estimates of prognosis are the result of an
objective process. Prognosis is a forecast of clinical outcome and its clinical utility is intertwined
with patient and family understanding and perspective. Consequently, prognosis makes
objectivity an essential component of clinical reasoning, medical decisions, and nursing actions
because of risk of harm to the patient (e.g., withholding care when benefit outweighs risk) (Zier
et al., 2008; Zier et al., 2012). Nurses and physicians must deliver impartial care and equip
patients and family members making treatment decisions with accurate information essential to
making value-based decisions regarding treatment (Dugas et al., 2017).
Moreover, nurses use aspects of prognosis to explain evidence-based rationale for care
and to be patient advocates while physicians rely on prognosis to justify treatment
recommendations. Engebretsen et al. (2016) noted that empirical objectivity is the scientific
approach to asking, “Did I observe and/or imagine the situation in the right way?” Objectivity
and tools that help clinicians objectively determine probability of mortality is a way of reducing
the subjectivity in clinical observations (i.e., predicting short-term prognoses). From this
position, objective knowledge is important when subjective views are antithetical to the reality of
either favorable or unfavorable short-term outcomes in the ICU.
Research Questions
The primary aim of this study was to answer the question, “Which prognostic scoring
system performs 30-day mortality predictions most accurately for critically ill cancer patients
admitted to the ICU?” Once identified, the tool with optimal performance can subsequently serve
as the model that augments CCN views and advocacy at the bedside as well as inform clinician
perceptions, clinical judgment and treatment recommendations. Essentially, the focus was
identifying performances of vPMs as a source of objectivity for later use to inform nurse
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knowledge and actions as well as physician-based clinical reasoning, which leads to information
sharing with patients and families when appropriate.
Overall, the objectivity of the outcome serves as evidence for conversations about the use
of vPMs in reducing the subjective nature of both nurse and physician perceptions about patients
with a cancer diagnosis in the ICU. Evidence generated from this meta-analysis to answer the
research question was a way of identifying a vPM that can be used to build concordance between
nurse-physician perspectives at the bedside and application to decision support for patients and
families. Because of the availability of three vPMs, the choice of an objective tool offers the
impartiality needed when sharing prognosis-related information with patients and families during
the shared decision-making process.
The secondary aim was to answer the question, “Among the study sample, what
physiological variables are reported to be additional independent predictors of 30-day mortality
for oncology patients in the ICU?” By answering this question, clinicians can use the findings to
expand clinical knowledge regarding the degree of influence adjunctive physiological variables,
not captured in the models, play in SOI scores and estimating risk of 30-day ICU mortality. The
answers to both the primary and secondary questions contextualize the use of prognostic scoring
systems in critically ill oncology populations. The findings are expected to help CCNs better
understand the role of vPM use at the bedside and specific application to the care of oncology
patients. For both CCNs and intensivists, the discussion of findings should expand professional
knowledge of vPM value to the diversity of ICU patients and how futile care are perceived to
healthcare professionals at the bedside.
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Definition of Terms
Conducting a meta-analysis centered on the performance outcomes of ICU-based
predictive tools and explaining the statistical methodology involves understanding the meaning
of Bayesian terminology. Key terms are defined as follows.
Area under the ROC curve (AUC). Area under the curve measures the correlation
between the category predicted by the test and the true category into which the case falls
and how often predictions and outcomes are concordant (Gonen, 2007; Munro, 2005).
The closer the AUC is to 1.0 (e.g., 0.80) the better the performance of prognostic model
is at making accurate predictions. For example, an AUC value of 1.0 means the test is
perfectly accurate. The practical lower limit for the AUC of a diagnostic test is 0.5
(Gonen, 2007).
Calibration. Calibration is the degree of agreement between a model’s predicted
probabilities and true (or observed) probabilities using general linear model (GLM).
Cohort. A cohort is a group of subjects sharing a defining characteristic particularly,
patients grouped according to the vPM model used to predict mortality.
Discrimination. Discrimination is the degree to which a probability model is able to
distinguish between survivors and non-survivors within a 30-day interval (Afessa,
Tefferi, Dunn, Litzow, & Peters, 2003; den Boer, de Keizer, & de Jonge, 2005).
Performance. In this study, performance refers to a statistical expression reflecting the
degree of concordance between predicted outcome and observed outcome (den Boer, de
Keizer, & de Jonge, 2005; Gonen, 2007).
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Predictive accuracy. Predictive accuracay is a statistical phrase referring to a
calculation of the probability that the test result and prediction agree; the overall
precision of a test in measuring true findings. (Munro, 2005).
Summary
Scientific advancements in recent years have resulted in better treatment protocols,
greater cure rates and declining mortality rates within the cancer population (NCI, 2015a; NCI,
2015b; Ryerson et al., 2016; Siegel, Miller, & Jemal, 2015). Despite improvements in treatment
approaches and supportive care measures, there are instances when patients with active cancer
diagnoses require care most befitting in the ICU. The heterogeneity of the critically ill cancer
population and varying nature of disease (i.e., curability, reversibility, control, or terminal)
makes broad negative assumptions about ICU survival inappropriate. Although the risk of
delivering futile care is a legitimate concern in the ICU, the extent of medical intervention cannot
be determined by diagnosis of cancer alone. This reality requires ICU survival be reconceptualized because of diversity in clinical presentations, needs, and available resources to
manage critical illness.
Based on research, reluctance among critical care nurses and intensivists to admit
critically ill cancer patients to the ICU is attributed to fatalistic views and beliefs about poorer
outcomes associated with an active cancer diagnosis (Bird et al., 2012; Kopterides et al., 2011;
Neville et al., 2015). In addition, critical care staff have reported experiencing apprehension
towards delivering costly care that is perceived as having no benefit to 30-day survival in the
ICU (Bos et al., 2015; Cruz, Camalionte, & Caruso, 2015; Kim et al., 2014; Markou,
Demopoulou, & Myrianthefs, 2008; Sibbald, Downar, & Hawryluck, 2007). These views persist
in spite of improved management strategies available to reverse untoward treatment effects,

21

control disease, and restore health. Competing factors (set beliefs and perceptions versus patient
characteristics and advancements in treatments) cause predicting 30-day ICU mortality to be a
conundrum for critical care staff in the absence of an objective medium.
Referencing a prognostic tool is an opportunity to weigh the benefits and risks involved
in ICU admission without bias when triaging cancer patients (Cavallazzi et al., 2009). While
seeking to provide fair distribution of available ICU resources during triage decisions, clinical
inclinations are directed towards ICU patients who are mostly likely to survive if admitted
(Blanch et al., 2016). Unfortunately, triaging is taking place under conditions by which decisions
for or against ICU admission of cancer patients are often inappropriately focused on the
underlying malignant disease rather than the physiological parameters representative of mortality
outcomes (Blanch et al., 2016; Cavallazzi et al., 2009; Horster et al., 2012).
Nevertheless, the mathematical probabilities of mortality risk, generated by vPMs, inject
objectivity early into the ICU stay (applied within first 24 hours of admission). When applied at
admission, the timing of vPM application addresses the subjectivity of traditional beliefs
influencing how cancer patients are perceived and concerns about futile care in the early hours of
admission to the unit. When used appropriately, vPMs function as objective tools that inform
critical care management, critical care nursing action, and support patients and families
understanding about the direction of care.
Appropriate use indicates healthcare professionals acknowledge patient-family
informational needs. Application also reflects attempts to address anxieties in order to better
facilitate the decision-making process in response to both favorable and unfavorable prognoses.
The information derived from vPMs does not replace clinical judgment; rather, vPMs add
impartial information to clinical reasoning and aid the decision-making process. The intent of
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vPM use is to reduce variability in perceptions between nurses at the bedside and intensivists so
that patients and family members receive congruent information from staff (Gaeta & Price,
2010). By reviewing and analyzing the literature, additional insights about the performance of
vPMs in the cancer population and identification of variables influencing their predictive
accuracy broadens the understanding of clinical utility among nursing and medical practice. The
intent is translatable findings applicable at the bedside.
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Chapter 2
Review of the Literature
Admission to the ICU requires consideration for weighing the benefits of providing
advanced life sustaining measures against the risk of excessive measures that do not reverse
physiological insult to health. Employing aggressive treatment approaches that do not result in
quantifiable or qualitative improvements to patient outcomes (i.e., meaningful survival) is
perceived by many critical care staff to be futile care (Cruz, Camalionte, & Caruso, 2015; Louie,
et al., 2013; Mohammed & Peter, 2009; von Gruenigen, & Daly, 2005). Moreover, research has
shown that ICU clinicians (i.e., intensivists, critical care nurses) continue to reluctantly admit
severely ill cancer patients to critical care units because of perceptions of poor prognoses,
concern for excessive consumption of resources, and assumptions of delivering costly care that is
deemed futile (Bird, Farquhar-Smith, Wigmore, Potter, & Gruber, 2012; Horster et al., 2012;
Sibbald, Downar, & Hawryluck, 2007).
Advances in the management of malignancies and complications of treatment resulting in
improved survival outcomes make traditional views of cancer patients as poor candidates for
admission to the ICU unjustified (Aygencel, Turkoglu, Turkoz-Sucak, & Benekli, 2014;
Staudinger et al., 2000). Investigations into ICU mortality among critically ill cancer patients
reveal that survival outcomes are comparable with severely ill non-cancer patients (Bird et al.,
2012; Ñamendys-Silva et al., 2010; Ñamendys-Silva et al., 2015). Moreover, data demonstrating
increase survival rates support the need to incorporate objective modes of determining prognosis
into the care planning process.
Distinguishing between medical and surgical causes as well as underlying co-morbidities
adds to the complex nature of clinical observation-derived prognoses. Clinical observations in
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tandem with negative perceptions and assumptions can distort mortality predictions (Gigerenzer
& Edwards, 2003; Zier et al., 2012). When outcomes are poorly conceptualized (i.e.,
misperceptions of prognosis), patients and families can potentially be harmed by receiving
inaccurate information (Gigerenzer & Edwards, 2003; White et al., 2016). In addition, the
existence of inter-professional discordance in observations along with biases between critical
care nurses and intensivists tend to breakdown collaborative decision-making efforts (Neville et
al., 2015; Turnbull et al., 2014). Therefore, objective tools that inform nurse and physician
assessments of complex, somber issues inherent to the care of critically ill patients have
prognostic implications for guiding care (Neville et al., 2015).
While it is important to recognize that patients with an active cancer diagnosis, including
metastatic disease, now have better chances of survival, uncertainty about surviving a 30-day
stay in intensive care persists for both patients/families and non-oncology ICU nurses and
physicians (Huffines et al., 2013; LeBlanc, Kenny, O'Connor, & Légaré, 2009; Torres et al.,
2016). Thoughts of poor prognoses are not unfounded when examining certain patient situations.
For example, the uncertainty about a poor prognosis is diminished among patients with wellestablished terminal illnesses attributed to advancing malignancy and/or irreversible organ
failure related to treatment. Through variations and differences in cancer patients needs, clinical
presentations serve as the impetus for re-conceptualizing ICU cancer survivors and nonsurvivors. Prognostic models are the objective approach to mediating clinical judgment when
patients are at-risk for biased beliefs about delivering futile care and related outcomes.
Prognosis
Accurate prognosis in the acute care setting is central to clinical decision-making because
of its direct relationship to patient outcomes (Mallet et al., 2010). As the endpoint of care,
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nursing processes and medical approaches involve patient health status, disease characteristics,
and treatment preferences. Together, these factors and related variables determine patient
treatment options, inform the direction of care and are influential in predicting short-term
survival outcomes (e.g., 30-day ICU survival) (Bird, Farquhar-Smith, Wigmore, Potter, &
Gruber, 2012; Bos et al., 2015). Inclusion of prognosis, timeliness of prognostic information, and
way of communicating prognosis-related information with patients and/or family decisionmakers, serves as the basis for setting realistic expectations in the ICU (Hutchison et al., 2016;
LeClaire, Oakes, & Weinert, 2005).
Favorable and unfavorable prognoses in oncology patients are not always apparent at the
bedside. Cavallazzi et al. (2009) explained that critically ill patients with malignancies are a
heterogeneous group with varied prognoses and specific factors have been associated with
different outcomes. Prognostic tools are a way of deciphering between patients most likely to
survive and critically ill cancer patients who may not benefit from aggressive treatment
approaches (Bos et al., 2015; Moons et al., 2009; Suhag et al., 2014). In this instance, the
subjective nature of biases at the bedside are replaced with objective measurements of mortality
risk with the use of vPMs. However, discussions about the relationship between prognosis and
the role of vPMs in allaying concerns about delivering futile care in the oncology population is
absent from the literature.
Prognostic Models
The original development of prognostic models began more than 35 years ago as a means
to predict the short-term risk of death (30-day ICU mortality) for ICU patient groups (Vincent &
Moreno, 2010). The Acute Physiology and Chronic Health Evaluation II (APACHE II),
Simplified Acute Physiology Score II (SAPS II) and Sequential Organ Failure Assessment
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(SOFA), are among a few general ICU vPMs available for the adult population (i.e, 18 years and
older). These three vPMs are well-established and most frequently used generic prognostic
indices reported in the literature (den Boer, de Keizer, & de Jonge, 2005; Tang et al., 2005;
Vincent & Moreno, 2010). As popular prognostic tools, APACHE II, SAPS II, and SOFA are
readily available online and in the format of “apps” downloaded to personal computers and
mobile devices (e.g., Smartphone, tablet computer) at no cost or via subscription to individual
users, institutions, and hospital systems. The requirements of use for each vPM are limited to
entering the value of the specified physiological variables (e.g., age, hematocrit, temperature) for
statistical computation similar to a calculator.
The collection of physiological variables for APACHE, SAPS, and SOFA were selected
by way of expert consensus, weighted for mortality prediction through use of statistical modeling
techniques, with estimated risk established using multiple logistic regression models (Knaus,
Draper, Wagner, & Zimmerman, 1985; LeGall, Lemeshow, & Saulnier, 1993; Vincent et al.,
1996). The overall aim was to quantify the natural disease process within the context of
therapeutic interventions based on objective criteria. This led to the selection of certain
physiological variables routinely measured in the ICU and managed therapeutically in response
to clinical aberrations (see Appendix A). These are the combined physiological variables
contained in all three vPMs.
Based on the principles of homeostasis, each physiological variable used in a model is an
independent predictor of survival outcome. For example, variables representing poor kidney
function (creatinine > 4mg/dl), compromised immunity (white blood cells [WBC] < 2.0), and
severe respiratory failure (partial pressure of oxygen [PaO2] <80 mm Hg), are signs of
homeostatic imbalances driving critical illness and influencing survival outcomes. For clinical
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feasibility purposes, particular considerations were given to common variables measured in the
ICU that capture homeostatic disequilibrium. Physiological factors like blood pressure, platelets,
fraction of inspired oxygen (FiO2), arterial acidity (pH), serum bicarbonate and bilirubin, are
accessible in intensive care settings yet objective measurements of physiological health.
Because of the unique characteristics of care in the ICU, conditions of care such as
whether or not a patient is receiving mechanical ventilation and use of vasopressors are also
included in models’ formulae. Specific to model design concerns, focus was directed at simple
and practical applications at the bedside for all three vPMs. To promote use, clinical
practicability involved interventions that did not go beyond usual activities performed regularly
by CCNs and intensivists. For example, the neurological component of the vPMs relies on the
Glasgow Coma Scale (GCS) routinely performed by the bedside nurse. This led to reasonable
steps to generate mortality risk predictions that are documented with simplicity in the ICU
medical record, communicated among healthcare professionals, and shared with patients and
families.
The limitation of vPM use entails every field being accurately populated to produce a
SOI score and corresponding percentage of estimated mortality risk (e.g., SAPS II total score =
72 points with estimated mortality 86%). Patient needs must align with the physiological
parameters of the vPMs for clinical usefulness. Appropriate use requires physicians to order
laboratory values, particularly, a basic metabolic panel (BMP), complete blood count (CBC), and
bilirubin. In addition, the CCN must receive orders for cardio-respiratory monitoring (including
arterial blood gases [ABGs]). Missing data interferes with complete assessment of prognosis;
therefore, calculations cannot be performed.
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Over time, newer versions of original models (i.e., APACHE to APACHE II and SAPS to
SAPS II) have been adapted to accommodate changing patient demographics, disease
prevalence, and advancements in intensive care practices. Because of these factors and
substantial variations in SOI across different ICU populations, vPMs apply case mix adjustments
to statistical formulations and estimates (Livingston et al., 2000). That is, each prognostic model
performs statistical procedures to permit comparison of outcomes between providers with
differing mix of ICU patients, which allows for validation across multi-unit/site/geographical
locations. The development of each vPM takes into consideration broad implications for ICU
admission and contributing factors influencing the probability of change in the outcome measure
(30-day survivor versus non-survivor) as a means for accommodating heterogeneity in the ICU
population (Pappachan, Millar, Bennett, & Smith, 1999).
As stated earlier, vPMs rely on the aggregation of worst values of physiological factors
(case mix variables) captured within the first 24 hours of admission. These factors are combined
to generate a score that is predictive of ICU-based mortality for each patient. The raw scores are
stratified into prognostic indices with higher scores strongly correlating with mortality. Using the
rule of general linear model (GLM), the score at time 1 (< 24 hours) is considered the strongest
predictor of outcomes due to regression artifacts (Campbell, 1996). Consequently, the raw score
(based on worst values) is included in the prediction model for estimating 30-day ICU mortality.
Repeated measurements beyond the initial 24-hr monitoring period have not shown to improve
vPMs’ predictive accuracy (Ferreira et al., 2001; Ho et al., 2007; Minne, Abu-Hanna, & de
Jonge, 2008).
The reliability and validation (criterion-related and external validity) of each vPMs’
performance (predictive accuracy) are based upon “discrimination” and “calibration” (Keegan &
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Soares, 2016). Discrimination refers to a model’s ability to make predictions by differentiating
between 30-day ICU survivors and 30-day ICU non-survivors with accuracy. It is reported using
the area under receiver operating characteristic curve (AUC) which is expressed in the form of a
correlation coefficent ranging from 0 to 1 and displayed via a GLM graph.
Discrimination quantifies the accuracy of predictions whereby perfect accuracy is
equivalent to an AUC of 1. An AUC closer to 0 is indicative of poor discrimination (e.g., AUC
0.35). For example, a prognostic model predicted 75% mortality within a sample of 100 patients
and 75% of the patients died, the AUC will be 1. However, an AUC of .5 indicates the model
prediction is equivalent to chance (Keegan & Soares, 2016). It is also another way of describing
sensitivity and specificity (i.e., true positive and true negative cases) within the context of
prognostic tools. Sensitivity and specificity testing is used to form the receiver operating
characteristic curve (ROC) and AUC is the product of sensitivity and specificity results.
Table 1 shows the parameters of the scale. The scale ranges from 0 to 1 with 0.5 equivalent to
chance. For the scale to be meaningful in the clinical setting, it must perform at 0.7 or better.
Table 1.
Classifying Predictive Accuracy of a Prognostic Test*
Performance Range
.90 – 1

Rating
Excellent

Grade
A

.80 – .89

Good

B

.70 – .79

Fair

C

.60 – .69

Poor

D

.50 – .59

Fail

F

*Reference ranges retrieved from den Boer, S., de Keizer, N. F., & de Jonge, E. (2005). Performance of prognostic models in critically ill cancer
patients - a review. Critical Care, 9(4), R458-463. https://dx.doi.org/10.1186/cc3765
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As a complement to discrimination, calibration is the degree of agreement between a
model’s predicted probabilities and true (or observed) probabilities using GLM. It answers the
question, “Are the predictions of the model reliable?” (Vergouwe, Steyerberg, Eijkemans, &
Habbema, 2002). Calibration is reported statistically using the Hosmer-Lemeshow (H-L)
goodness-of-fit test, which gives a chi-square statistic (den Boer, de Keizer, & de Jonge, 2005).
When the H-L yields a p value greater than 0.05, it is an implication of good calibration while
small p values (high H-L statistics) indicate lack of fit (Dreiseitl & Osl, 2012; Hosmer, Hosmer,
Le Cessie, & Lemeshow, 1997; Vergouwe et al., 2002). When reviewing the literature centered
on the performance of prognostic models, authors must report discrimination and calibration to
establish validation of vPMs within the respective studies.
External validity is strengthened when study settings include different ICUs, institutions,
and/or countries. Mixed populations also expand models’ generalizability when good
discrimination and validation are achieved under scientific rigor. When reviewing the literature,
the aim is to identify validation studies with large samples, diverse populations, multi-sites, and
varying geographical locations to establish validation of vPMs that will be used to answer the
primary research question. For the aforementioned reasons, APACHE II, SAPS II, and SOFA
were presumed to fit the criterion resulting in these models being the focus of the literature
review.
APACHE II in the Literature
The Acute Physiology and Chronic Health Evaluation II (APACHE II) is most widely
used among prognostic systems around the globe; thus, making it the default gold standard for
assessing disease severity on admission to the ICU and formulating outcome predictions (Knaus,
2002; Tang et al., 2005). It currently uses 12 physiological variables and incorporates immuno-
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compromised status into its probability prediction (see Appendix B). The score ranges from 0 to
71 with a score of 60 points equaling an estimated mortality of 99.5% as well as a score of 30
and 15 correlating with 75% and 25% risk of mortality, respectively (see Table 2).
Table 2.
Acute Physiology and Chronic Health Evaluation II*

*Publically available at: https://www.mdcalc.com/apache-ii-score

The APACHE prototype was developed in 1981, tested in two ICU settings (a university
and community hospital) and validated with 805 patients (Knaus et al., 1981). This original
version contained 34 physiologic variables with an increase in score closely correlating with 30day ICU mortality. The model was then revised 4 years later, in 1985 (APACHE II), to simplify
use and increase clinical utility while maintaining the statistical accuracy of the model (Knaus,
Draper, Wagner, & Zimmerman, 1985). As a multi-institutional validation study, researchers
applied APACHE II in 13 mixed medical-surgical ICUs in the United States. This follow-up
study was conducted prospectively between 1979 and 1982 with an enrollment of 5,815 patients
(admitted for post-operative, non-operative, emergency, and/or severe chronic conditions
monitoring); patients with cancer were included (Knaus, Draper, Wagner, & Zimmerman, 1985).
Specifically, all 13 hospitals had a percentage of cancer patients in the study that ranged from 111% (Knaus et al., 1985).
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Both the developmental and validation studies established APACHE II’s clinical validity
after it was found to have both good discrimination (> 0.8) and calibration (p > .05) as well as
generalizable to the ICU population-at-large (Knaus et al., 1981; Knaus et al., 1985). To date, the
APACHE II continues to be used and its performance studied worldwide in general and selects
ICU patient mixes that include multi-center locations (Livingston et al., 2000, n = 10,393; Nobile
et al., 2016, n = 469; Vassar et al., 1999, n = 2,414). As the perceived gold standard among
vPMs, researchers have sought its appropriateness for application in high mortality risk groups.
High-risk ICU sub-groups identified in the literature were diverse. Model performance
among patients with cancer showed good discrimination (Chang et al., 2006, n = 1,263, AUC
0.86, H-L p = 0.58 ). Model performance among patients with cardiac disease was also good
(Argyriou et al., 2015, n = 300, AUC 0.84, H-L p = 0.15). When APACHE II was applied to
trauma patients (Hwang et al., 2012, n = 706, AUC 0.95, H-L p = 0.3), those with various
infections (Williams et al., 2016, n = 8,871, AUC 0.90, H-L p = 0.53), and pulmonary embolism
(Chen et al., 2017; n = 55,967, AUC 0.923, H-L p 0.23), it showed excellent discrimination. The
ability of APACHE II to discriminate among end stage liver disease patients (Wernly et al.,
2017, n = 4,381, AUC 0.76; H-L not reported), cirrhosis (McPhail et al., 2015, n = 971, AUC
0.768, H-L p = 0.78), cerebral hemorrhage (Huang et al, 2016, n = 546, AUC 0.76, H-L 0.84);
after in-hospital cardiac arrest (Senaratne & Veenith, 2015, n = 261, AUC 0.706, H-L not
reported) and individuals over the age of 90 (Haq et al., 2014, n = 951, AUC 0.74, H-L not
stated), proved to be less accurate with predicting mortality among the groups studied.
Some validation studies focusing on sub-groups did not include goodness-of-fit tests
results. This limited the ability to accept validation solely based on a model’s discrimination
(reporting AUCs) in those studies. When compared to other generic vPMs (e.g., SAPS II, SOFA)
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using both prospective and retrospective study designs, the results have shown good and
comparable discriminative ability for predicting outcomes but APACHE II did not always
emerge as the superior performing model (Livingston et al., 2000; Nobile et al., 2016; Vassar et
al., 1999). Mixed results were identified in APACHE II validation studies centered on cancer
patients making it a challenge to establish it as a superior performing prognostic tool in this
population (Afessa et al., 2003; Benoit et al., 2003; Berghmans et al.,2004; Schellongowki et al.,
2004; Sculier et al., 2000; Soares et al., 2004).
Lastly, the literature review included a search for systematic reviews. Only one of the
three systematic reviews identified discussed oncology patients. In this study, APACHE II
performance was compared with five other models (including SAPS II but not SOFA) in the
critically-ill cancer population (den Boer, de Keizer, & de Jonge, 2005). Among the 10 articles
reviewed, only six included APACHE II. The authors surmised that large study design variations
made it difficult to perform meaningful comparisons (den Boer et al., 2005). Because of these
findings, the optimal performance of APACHE II in the oncology sub-population remained
unknown.
SAPS II in the Literature
The Simplified Acute Physiology Score (SAPS) is a validated tool that uses 14
physiological variables for its statistical formulation, which produces a raw score. It also
incorporates “age”, “type of admission” (scheduled surgical, unscheduled surgical, or medical),
and the presence or absence of three underlying disease variables (acquired immunodeficiency
syndrome, metastatic cancer, and hematologic malignancy) into its statistical equation (see
Appendix C). The score ranges from 0 to 163 points with a score of 52 points corresponding with
50% mortality, 64 points equaling an estimated mortality of 75% while 77 points yields an
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estimated 90% mortality risk (see Table 3). The reliance on continuous variables and categorical
variables to devise mortality predictions is the reasoning for GLM statistical approach.
Table 3.
Simplified Acute Physiology Score II*

*Publically available at: http://clincalc.com/IcuMortality/SAPSII.aspx

It was initially developed in 1984 and applied in eight ICUs with 679 patients
participating (Le Gall et al., 1984). It then underwent revision (SAPS II) in 1991and 1992 to
refine its probability calculations for converting a raw score into the probability of in-hospital
mortality (LeGall, Lemeshow, & Saulnier, 1993). The revised version was developed and
applied prospectively. The study analyzed the predictive accuracy of SAPS II among 13,152
patients recruited in 137 medical, surgical, and mixed ICUs from 12 countries (North America
and Europe) spanning a 3 month period in 1992 (LeGall et al., 1993).
Each study participant got randomly assigned to the “development” data sample (65%) or
“validation” data sample (35%). The study excluded patients under the age of 18, those who
were burn victims, and individuals with coronary care needs (including cardiac surgery) from
both samples. The patient mix included those with malignancies (solid and hematological) and
receiving chemotherapy. In the findings, LeGall, Lemeshow, and Saulnier (1993) reported good
discrimination (AUC 0.88) and calibration (H-L p = 0.883) for the developmental sample. The
validation sample performed similarly with good discrimination (AUC 0.86) and very well with
its goodness-of-fit test (p = 0.104).
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Since its development, additional validation studies have been conducted to evaluate
SAPS II performance with other generic vPMs such as comparing it with APACHE II in general
ICU case mixes (Godinjak et al., 2016). Godinjak et al. (2016) reported good discrimination,
AUC 0.892 and AUC 0.920, for SAPS II and APACHE II respectively in a sample of 174
patients. In addition, Pearson’s correlation was used to evaluate the relationship between these
two vPMs. The researchers found a positive correlation that was statistically significant between
the values of SAPS II and APACHE II (r = 0.708; p = 0.001).
Lemeshow and LeGall (1994) conducted a systematic review to compare prognostic
tools and determine their clinical usefulness. The authors concluded that the evidence supported
SAPS II application in assessing prognosis, comparing ICU performance, and stratifying patients
for clinical trials. Nevertheless, SAP II model performance in the oncology ICU sub-population
was not discussed. This resulted in an identified gap in the literature and interest in further
investigation.
International validation studies exploring the predictive performance of SAPS II were
also identified in the literature. These studies were conducted inside and outside of the United
States. Nobile et al. (2016) investigated its clinical validity in 730 ICUs located in 84 countries
but the sample was small (n = 469 patients) relative to the study design. Livingston, et al. (2000)
performed a large study in Scotland covering 22 ICUs with 13,291 participants but the
percentage of cancer patients was not disclosed in the study characteristics or findings. Sakr et al.
(2008) study was set in a German university hospital with 1,851 patients. In each of these
validation studies, SAPS II demonstrated the best discrimination in comparison with APACHE II
but superior calibration over APACHE II was not established. In addition, the investigators did
not report the distribution of cancer patients.
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More recently, the performance of SAPS II among ICU sub-groups has also been studied
to further establish its clinical validity. Outcomes in groups like patients with end stage liver
disease (Wernly et al., 2017, n = 4,381, AUC 0.78, H-L not stated), cirrhosis (McPhail et al.,
2015, n = 971, AUC 0.781, H-L p = 0.78) and individuals over the age of 90 (Haq et al., 2014, n
= 951, AUC 0.75, H-L not stated), showed SAPS II performing fair discrimination and good
calibration when reported. This model also showed excellent discrimination and calibration
among patients with infectious diseases (Williams et al., 2016, n = 8,871, AUC 0.90, H-L p =
0.68). These findings suggest that SAPS II clinical validity and external validation varies among
sub-groups in the ICU.
In the cancer ICU sub-population, SAPS II was matched with APACHE II in patients
with only hematological malignancies (Benoit et al., 2003) and hematologic/solid tumor case
mixes (Schellongowki et al., 2004). Benoit et al. (2003) reported fair discrimination for SAPS II
(AUC 0.77) and APACHE II (0.71) with good calibration, 0.60 and 0.39, respectively.
Schellongowki et al. (2004) findings showed superior performance for APACHE II (AUC 0.83)
over SAPS II (AUC 0.78) with good calibration for both (APACHE II = p 0.058; SAPS II = p
0.066). On the other hand, Sculier et al. (2000) conducted a comparison study that included
patients with metastatic disease that showed poor discrimination (APACHE II AUC 0.60; SAPS
II AUC 0.67) and poor calibration (APACHE II p 0.001; SAPS II p 0.001). Collectively, these
results are mixed resulting in the optimal performance of SAPS II in the oncology population yet
to be determined.
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SOFA in the Literature
The Sequential Organ Failure Assessment (SOFA) is an organ failure based prognostic
system and an established predictor of mortality in critically ill patients (Akbar, Shahzadi,
Khurram, & Khar, 2016; Vincent et al., 1996). Differing from APACHE II and SAPS II, the
SOFA model was created based on the premise that multiple organ failure is a major cause of
morbidity and mortality in the critically ill patient and can be assessed repeatedly to define a
patient’s progress (Vincent et al., 1996; Vincent, Ferreira, & Moreno, 2000). Using physiological
variables representative of six organ systems (lungs, bone marrow, brain, heart, kidney, and
liver), the SOFA model produces score ranges from 0 to 24 points (see Appendix D). Scores
closer to 24 are indicative of greater chance of 30-day ICU mortality (see Table 4).
For example, A score of 12 corresponds with an estimated mortality ranging from 40% to 50%
versus a score of 17 points equaling an estimated mortality risk > 90%.
Table 4.
Sequential Organ Failure Assessment *

*Publically available at: http://clincalc.com/IcuMortality/SOFA.aspx

The historical development of the SOFA model began in 1994 with a panel of critical
care medicine experts. The panel of experts hypothesized that the development of new
therapeutic interventions aimed at reducing the severity of organ dysfunction in the ICU called
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for better ways to objectively quantify SOI (Vincent et al., 1996). The group posited that the way
patients are treated in ICUs as well as therapies used by intensivists to manage organ failure,
may change over time. Therefore, a model needed to be constructed with deliberation for how
therapeutic advancements and management strategies influence outcomes. This process required
a more systematic, objective means for quantifying organ failure to accommodate changing
paradigms.
These intentions gave sway to development studies identifying important predictors of
mortality (i.e., respiratory-, coagulation-, neurological-, cardiovascular-, renal-, and liver-related
variables). Considerations for treatment response and disease progression were parts of the
process to successfully establish SOFA’s predictive performance (Vincent et al., 1998; Vincent
et al, 2000). The actions of model developers subsequently led to validation studies in general
ICUs (Toma et al., 2007, n = 6,276, 1 ICU; Toma et al., 2008, n = 2,928, 1 ICU; Ho, 2007, n =
1,311, 1 ICU; Timsit et al., 2002, n = 1,685, 6 ICUs; Rivera-Fernandez et al., 2007, n = 6,409, 55
ICUs) and ICU sub-populations in mixed medical-surgical ICU settings (Ferreira et al., 2001, n =
352; Gosling et al., 2006, n = 431; Moreno et al., 1999, n = 1,449; Zygun et al., 2005, n = 1,436).
In addition, the model has been applied across different institutions and geographical locations
(Toma et al., 2007, Vincent & Moreno, 2010; Zygun et al., 2005).
There were four validation studies identified that compared admission SOFA predictions
with APACHE II’s performance in medical and surgical ICU patients. Ho et al. (2007) reported
AUCs for SOFA and APACHE II, 0.791 and 0.858, respectively among a population of 1,311
patients. Holtfreter et al. (2006) also conducted a retrospective investigation (n = 933) into the
performance of SOFA (AUC 0.72) and found it discriminating more closely to APACHE II
(AUC 0.785) but with less accuracy in comparison with the Ho study. Peres-Bota et al. (2002)
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approach was a prospective, observational study with 949 patients whereby both models showed
good discrimination but APACHE II (AUC 0.88) performed slightly better than SOFA (AUC
0.872). On the other hand, Gosling et al. (2006) employed a prospective approach (n = 431) with
both SOFA (AUC 0.61) and APACHE II (AUC 0.62) showing similar, yet poor discrimination.
Janssens et al. (2000) conducted a prospective investigation (n = 303) with SOFA (AUC
0.82) demonstrating superior discrimination in comparison with SAPS II (0.77). Granholm et al.
(2016) performed a post hoc study resulting in SOFA (0.73) not discriminating as well as SAPS
II (0.80). There was one study identified that compared all three models in a large general
hospital in Pakistan. The study enrollment was small with only 96 eligible medical ICU patients
(Naqvi et al., 2016). Descriptions of cancer patient makeup were not elucidated in the
demographics section. Nevertheless, APACHE II showed somewhat better calibration (p 0.866)
in comparison to SAPS II (p 0.0811) and SOFA (p 0.32). With an AUC of 0.835, the APACHE
II model showed superior discrimination power to SAPS II and SOFA which both predicted at
the same degree of accuracy, AUC = 0.75. Based on these findings, further exploration of SOFA
application and optimal performance in the oncology ICU sub-population are warranted, to add
to the current body of research.
Bedside Context for Prognostic Models
Because clinical judgment alone is difficult and imprecise, the intent of prognostic model
use is to objectively inform clinical judgment; not to replace clinical interpretations or serial
assessments (Hamel et al., 1999; Knaus et al., 1995; Teno et al., 2000). Prognostic models are to
be regarded as adjunct, objective tools rather than substitutes for clinical judgment and are
available for use in the shared decision-making process (Feltracco et al., 2011). The application
of prognostic tools within patient-centered clinical pathways and algorithms may assist with
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informational needs; thus, ensuring ICU patients receive timely quality care from ICU nurses as
well as appropriately prescribed treatments by physicians involved in the care process
(Costantini, Alquati, & Di Leo, 2014; Constantini et al., 2014; Huffines et al., 2013).
Again, vPMs aid decisional needs by providing objective information about a patient’s
clinical status within the first 24 hours of admission to the ICU. These decisional needs are at the
center of patient/family directives and guide nurse-physician actions at the initiation of care
(Sepucha, Fowler, & Mulley, 2004; Stacey, Samant, & Bennett, 2008; Stacey, Paquet, & Samant,
2010; van Mol, 2016). When the use of prognostic models are understood and applied, nurses
use the information for patient advocacy and physicians rely on it to support treatment
recommendations (Neville et al., 2015) . The prognostic value is that patients and family as
surrogate decision-makers have objective information to address decisional needs that cause
uncertainty, reluctance, and desire for additional information (Barbini et al., 2014; Chien et al.,
2014; Djulbegovic et al., 2016; Becerra-Perez et al., 2016).
Summary
In summation, APACHE II, SAPS II, and SOFA have been studied in diverse ICU
settings (i.e., medical, surgical, neurological, trauma, oncology, cardiac, and surgical units)
which included sample sizes greater than 1000 patients on a worldwide platform (Cholongitas et
al., 2006; Godinjak et al., 2016; Hosseini & Ramazani, 2016; Naqvi et al., 2016; PietraszekGrzywaczewska et al., 2016). Most importantly, APACHE II, SAPS II, and SOFA have been
validated using large, prospective, multi-center, multi-national general ICU population mixes (up
to 16,000+ patients) that included patients with cancer (Cabré et al., 2005; Livingston et al.,
2000; Moreno et al., 1998; Moreno et al., 1999; Salluh & Soares, 2014; Vincent & Moreno,
2010; Yu et al., 2014). The findings support claims that each vPM is good at predicting patient
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outcomes (discrimination) and forecasting mortality (calibration) but with differing degrees of
predictive accuracy in general ICU populations (Godinjak et al., 2016; Knaus, 2002; Salluh &
Soares, 2014; Vincent & Moreno, 2010).
Moreover, the review of literature supported the premise that each model quantifies
disease severity, determines prognosis, and guides therapeutic interventions. Nevertheless,
optimal performance comparing APACHE II, SAPS II, and SOFA within the ICU oncology subpopulation remained to be determined. A more in depth appraisal of the literature (i.e.,
systematic review) and synthesis (i.e., meta-analysis) was an opportunity to answer the primary
research question. The process involved focusing solely on research dedicated to APACHE II,
SAPS II, and SOFA model applications in the critically ill cancer population. Conducting a
meta-analysis in this area of research serves as a reference for CCNs and intensivists to explore
how vPMs can be applied clinically when there is uncertainty, concerns about delivering futile
care, and decision conflicts.
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Chapter 3
Methods
The overall aim was to determine the predictive accuracy of each vPM by combining
study results from previous investigations evaluating individual performances of vPMs. Follow
up statistical analysis included pooling the data to compare overall performances to determine
greatest predictive accuracy among the three vPMs: APACHE II, SAPS II, and SOFA. No
human subjects were under investigation and no related ethical considerations were involved in
the process.
Research Questions
The following questions were addressed in this study:
1. Which prognostic scoring system performs 30-day mortality predictions most
accurately for critically ill cancer patients admitted to the ICU?
2. Among the study sample, what physiological variables are reported to be additional
independent predictors of 30-day mortality for oncology patients in the ICU?
Design
A meta-analysis using meta-regression with random-effects model to combine and
summarize the results of prognostic model validation studies was the study design. Validation
studies are the main way to assess or validate the performance of a vPM on a new patient
population. The design of validation studies are to compare predicted and observed mortality
outcomes for groups of patients (calibration) and to quantify the model’s ability to distinguish
between patients who do or do not experience the event of interest (discrimination) (Moons et
al., 2009). These studies tend to report performance outcomes in the form of AUCs.
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Procedures
The meta-analysis was performed following the Preferred Reporting Items for Systematic
Reviews and Meta-analysis (PRISMA) criteria (see Figure 2, pg. 45) (Liberati et al., 2009). An
extensive search of the literature for studies with similar performance aims (i.e., validating
predictive accuracy when computed within the first 24 hours of admission) were conducted using
the following search procedure. Literature searches of CINAHL, PubMed, Web of Science, and
Cochrane Library databases spanning January 2000 to February 2017 timeframe were completed.
Each literature search was limited to articles reporting critically ill oncology patients as the study
population and admitted to the ICU setting. Study participants in articles of interest were
confined to study populations admitted to the ICU for management associated with cancerrelated diagnoses.
The search included prospective and retrospective observational cohort studies using the
following key words and medical subject heading (MeSH) terms: “Acute Physiology and
Chronic Health Evaluation II (APACHE II)” “Simplified Acute Physiology Score (SAPS)”, and
“Sequential Organ Failure Assessment (SOFA)” with subheading “oncology”, “cancer”, “ICU”
and its derivates, “critically ill”, “prognostic model”, “prognostic scoring system”, “severity-ofillness scores”, “prognosis and outcome”, “prediction” and “mortality”. Search terms combining
key words with “AND” and “OR” were added for broader searches. Studies were full-text
English-language, peer-reviewed articles published between January 2000 and February 2017.
To identify additional studies, reference lists of all eligible articles were examined, crosschecked,
and included if eligibility requirements were met.
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Figure 2. PRISMA Flow Diagram
Reference: Moher, D., Liberati, A., Tetzlaff, J., Altman, D. G. The PRISMA Group (2009).
Preferred reporting items for systematic reviews and meta-analyses: The PRISMA Statement.
PLoS Med 6(7): e1000097. doi:10.1371/journal.pmed.1000097
Data Extraction and Collection
Data extraction followed the Checklist for Critical Appraisal and Data Extraction for
Systematic Reviews of prediction Modeling Studies (CHARMS) protocol (Figure 3) (Moon et
al., 2014). Data collection involved the use of study-level data instead of individual-level data.
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Study-level data collected were the performance results of APACHE II, SAPS II, and SOFA
models reported in peer-reviewed literature. Study-level data analyzed refers to the diagnostic
performance statistics, AUCs (see “Definition of Terms”) with standard error of the estimates
(SE), reported in each eligible study.
Area under the characteristics curve was used for data extraction because it represents the
degree of concordance between vPM prediction and observed mortality in the study population.
An AUC of 0.70 to 79 is “fair performance” with AUC 0.80 to 0.89 and 0.90 to 1.0 representing
“good performance” and “excellent performance”, respectively. Including SEs with its
corresponding AUC accounted for the standard deviations in each study sampling distribution.

Checklist Item

Example

 1. Prognostic versus
diagnostic prediction
model?

The aim is to predict future events
The aim is to detect disease status

 2. Intended scope of the
review?

Models to inform therapeutic decision-making
Models to inform referral or transfer patient

 3. Type of prediction
modelling studies?

Prediction model development with external validation
External model validation only

 4. Target population?

Patients with cancer
Patients with out-of-hospital cardiac arrest

 5. Outcome to be
predicted?

Specific future event such as “in-hospital” mortality
Specific disease status such deep vein thrombosis
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 6. Time span of
prediction?

30-day ICU mortality
31-day to 6 month mortality

 7. Intended moment of
using the model?

Models to be used upon admission to the ICU from ER
Models to be used post-operatively in ICU

Figure 3. CHARMS Key Items Checklist to Guide Systematic Review Process.
Based on Moons, K. G. M., et al. (2014) Critical appraisal and data extraction for systematic
reviews of prediction modelling studies: The CHARMS Checklist. PLoS Med 11(10): e1001744.
https://dx.doi.org/10.1371/journal.pmed.1001744

The sample included studies focused on the prognostic performance of APACHE II,
SAPS II, and SOFA models in the ICU-based adult oncology patient population. The shared aim
across studies was to validate vPMs ability to discriminate between patients who lived from
those who died. Model performances were based on discrimination (see “Definition of Terms”)
calculated within the first 24 hours of admission and endpoint was 30-day ICU mortality. Each
study included in the meta-analysis reported the AUC as its measure of discrimination. A study
was excluded if information was insufficient for data extraction.
To address the secondary research question, articles eligible to answer the primary
research question were reviewed for additional discussions centered on single physiological
variables explored for a relationship to ICU mortality. Physiological variables of interest were
limited to covariates in which univariate analyses were performed to detect a statistically
significant (p < 0.05) influence on ICU mortality. The intent was to identify and describe
physiological variables not captured in vPM algorithms but were found to be associated with 30day ICU mortality risk.
The principle investigator independently reviewed and extracted data from eligible
studies entered into a Microsoft Excel spreadsheet. Demographic data included information such
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as first author, year of publication, country of origin, sample size, setting, cancer type, study time
period, and study type. Specific performance-related data extracted included AUCs, standard
errors [SE], 95% confidence intervals, Hosmer-Lemeshow goodness-of-fit p value, and
estimation of mortality. To ensure data entry accurateness, data were cross-checked and final
recheck procedure was conducted prior to statistical analysis.
Statistical Analysis
Inferential statistical analyses were performed using MedCalc for Windows version 17.2
statistical software package (MedCalc Software, Ostend, Belgium). The AUCs with SE were
extracted from each study to calculate pooled AUCs to answer the primary research question.
When an SE for an AUC was not provided in a study, the reported number of survivors and nonsurvivors were used to estimate it with methods described by Hanley and McNeil (1982).
Publication bias was analyzed using Egger’s test (Egger et al., 1997) and displayed graphically
with a funnel plot.
To Test Heterogeneity
Statistical analyses were conducted on study-level data extracted from the eligible
articles. Meta-regression using random-effects model to test heterogeneity was performed on this
data to determine pooled AUCs results for APACHE II, SAPS, and SOFA. Summarizing pooled
AUCs provided a more precise estimate of model performance for each vPM (Haidich, 2010).
When heterogeneity is present, summary measures must be interpreted within the context of
understanding the nature of variability in and across the studies. Statistical heterogeneity is
implicit because the performance outcomes in the studies are untenable.
There was also the assumption of no single true effect (i.e., the outcome in each study is
the same) due to variations in the characteristics of study populations and methodologies applied
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from study to study. The premise is that clinical and methodological diversity increases the
chances of statistical heterogeneity (Preuss & Ziegler, 2014). Therefore, random-effects
modeling was applied because it assumes 1) variability in study designs, 2) that differences in
underlying study populations exist, and 3) outcomes will vary across studies.
First, data was grouped according to prognostic model and then random-effects modeling
was added to statistical analysis to account for between-study variance (τ²). The random
variation within the studies plus the variation between the different studies was addressed using
this method. In random-effects modeling, the study variance is inversely weighted with the
heterogeneity parameter (Cochran’s Q test and Higgins I squared statistic) (Haidich, 2010;
Preuss & Ziegler, 2014). The summary weighted mean effect (i.e., weighted performance mean
for APACHE II, SAPS II, and SOFA) was then generated so that a pooled analysis would
determine greatest predictive accuracy among the three vPMs.
The heterogeneity of the pooled AUCs was measured using Cochran’s Q test and Higgins
I squared (I²) statistic. Statistical significance for the Q test was defined as p < 0.1 (because of
low power) and I² > 50 percentage. Statistical heterogeneity was expected because of the
methodological differences between the vPMs involved in making mortality predictions. For
example, the models differ in number and predictor variables such as the SAPS II uses blood
urea nitrogen versus SOFA uses serum creatinine to represent renal function. However, the
vPMs measure the same three physiological variables which are Glascow Coma Score for
neurological assessment and partial pressure of O2 in arterial blood [paO₂] with fraction of
inspired oxygen [FiO²]) to determine tissue oxygenation.
In summation, the random-effects model in this study produced a distribution of true
effects (a series of AUCs) with no missing data for all studies in each vPM group. The random-
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effects model combined true effects of these studies to estimate the weighted mean performance
because of τ² in each group distribution. This process resulted in summary AUCs for APACHE
II, SAPS II, and SOFA with single-value pooled estimates of the weighted mean performance
(i.e., mean distribution of AUCs) for each model distribution. After generating summary AUCs,
the pooled effects of APACHE II, SAPS II, and SOFA performances were compared to
determine the vPM with greatest predictive accuracy.
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Chapter 4
Results
The selection process using PRISMA criteria is shown below (Figure 4). Initially, 227
published articles were identified using the first search strategy. After screening titles and
abstracts, 57 potential studies were reviewed in full-text format. After reading these studies, 22
eligible validation studies met the inclusion criteria.
Description of Sample
A minimum of 10 studies for each vPM was sought to obtain meaningful interpretations
to support an evidence-based conclusion (Borenstein et al., 2009). The search yielded 22
validation studies reporting performance outcomes for the three vPMs in the critically ill
oncology ICU sub-population. Among the 22 validation studies, there were 16 articles, 15
articles, and 8 articles reporting AUCs for APACHE II, SAPS II, and SOFA models,
respectively. Some studies included more than one group of study subjects who underwent
mortality risk estimation by more than one vPM. As a result, the search yielded a total of 21
reported AUCs for APACHE II, 18 AUCs for SAPS II, and 10 AUCs for SOFA (see Appendix
E).
Key characteristics of the identified studies analyzed are shown in Appendix F. Together,
the 22 validation studies comprised 13 countries spanning four continents (Asia, Europe, North
America, and South America) and the Middle East. Study periods spanned the 1990s to 2011 in
228 hospitals with two independent studies conducted at one hospital in Mexico during the same
time-period. There were four categories of hospitals identified – university, university-affiliated
oncology specialty, tertiary oncology specialty, and tertiary community. All studies (12
retrospective cohorts, 10 prospective cohorts and one combined retrospective and prospective
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cohort) were set in adult medical and surgical ICUs. Eleven ICUs were dedicated to treating
oncology-only patients.
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A majority of the studies were validation studies testing the performance of the vPMs.
There were three out of the 22 validation studies that included testing a new model (model
development) while comparing the performance with established vPMs. Sixteen studies reported
findings for APACHE II (73%), 15 studies included SAPS II (68% ), and 8 studies (36%)
measured SOFA performance. A combined 14,644 patients with 25 cohorts (three studies had
two separate groups) comprised this study. The sample sizes ranged from 50 to 7,689 adult
oncology ICU patients. The oncology patient mix was 10 solid/hematological cohorts, three
hematological malignancies cohorts, three colorectal cancer cohorts, two solid tumor cohorts,
and one cohort each for: Acute Myeloid Leukemia, Acute Myeloid Leukemia with NonHodgkins lymphoma, gastric cancers, and gynecological cancers.
Some validation studies reported AUCs for two or more models. Other studies reported
AUCs for more than one sample population. This resulted in the performance of a vPM
sometimes reported more than once in an article to represent predictions performed on different
patient groups in the study (see Appendix E). For example, Cardenas-Turanzas et al (2012)
conducted a validation study evaluating the performance of SOFA in two cohorts: n = 540
medical ICU oncology patients and n = 783 surgical ICU oncology patients. The SOFA
performance was an AUC of 0.79 (0.024 SE) in the medical ICU group and 0.79 (0.063 SE) in
the surgical ICU group.
Models and Predictions in the Sample
In totality, there were 32,303 combined predictions performed among the three vPMs in
this meta-analysis. In the APACHE II cohort group, 16,764 mortality predictions were tested for
predictive accuracy across 22 validation studies. Among the SAPS II and SOFA cohort groups,
the models made 12, 960 (18 articles) and 2,579 (10 articles) total predictions, respectively. The
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combined findings from all predictions led to sorting outcomes into three groups of pooled
estimates to best summarize the overall performances of APACHE II, SAPS II, and SOFA
models.
Models Performance Statistics
For this study, the focus was on the discriminating power of vPMs. As stated earlier,
discrimination refers to a model’s ability to make predictions by differentiating between 30-day
ICU survivors and 30-day ICU non-survivors with accuracy. It is reported via the AUC, which is
expressed in the form of a correlation coefficent ranging from 0 to 1. Discrimination, measured
by AUCs, for APACHE II (n = 16,764 predictions) ranged from 0.60 to 0.94 with 0.80 mean
(95% CI 0.761 to 0.848, 0.095 SD, SEM 0.021, variance 0.008). Discrimination for SAPS II (n =
12, 960 predictions) ranged from 0.67 to 0.92 with 0.792 mean (95% CI 0.760 to 0.824, 0.063
SD, SEM 0.015, variance 0.004). Discrimination for SOFA (n = 2,579 predictions) ranged from
0.68 to 0.91 with 0.785 mean (95% CI 0.735 to 0.834, 0.069 SD, SEM 0.021, variance 0.004).
The data comes from different studies and diverse populations resulting in the need to
perform a goodness-of-fit test to account for potential discrepancies between predicted and
observed outcomes. The D’Agostino-Pearson to test for normal distribution of the true effects
(AUCs) was p = 0.467 (p > 0.05, accept normality) for the APACHE II model overall
performance in validation studies (Sheskin, 2011). The D’Agostino-Pearson test for SAPS II and
SOFA models overall performances were p = 0.983 and SOFA was p = 0.837, respectively.
Results of the D’Agostino-Pearson test indicate all models had normal distributions.
Independent samples t-test for assumption of homogeneity of variances was tested
between APACHE II and SAPS II model groups and APACHE II and SOFA model groups.
Homogeneity of variances was satisfied via F test for equal variances (p = 0.364). Considering
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there were unequal numbers in each cohort, the Welch test was performed for unequal variances,
F (23.4) = - 0.565, two-tailed p = 0.577. These steps were repeated between SAPS II and SOFA
model groups. Homogeneity of variances was satisfied via F test for equal variances (p = 0.738).
Welch test for unequal variances showed F (17.5) = 0.271, two-tailed p = 0.789. The results
were non-significant confirming no difference between the means of the three model groups.
Because the vPMs use different, yet similar combinations of physiological variables to
predict mortality, there was an assumption of independence among the performances of the three
models. Pearson product-moment correlation coefficient was computed to assess the relationship
between APACHE II and SAPS II. There was no correlation between the two models (r = -0.016,
p = 0.950). This step was followed by examining the relationship between APACHE II and
SOFA. This also showed no correlation between the two models (r = -0.185, p = 0.608). The
SAPS II and SOFA showed greater correlation (r = 0.290, p = 0.608) but lacked statistical
significance. This implies the vPMs are independently, discrete from one another.
Heterogeneity Testing
As stated earlier, meta-regression to test heterogeneity using random-effects model was
performed on study-level data to determine the summary AUCs for APACHE II, SAPS II, and
SOFA. The random-effects model (Zhou et al., 2002 method) was used to analyze the pooled
AUCs because heterogeneity was significant for all 3 vPMs (see Table 5) and the study sample
observed outcomes were expected to be varied. Statistical significance for the Q test was found
(Q = p < 0.001) and Higgins I² was > 50 percent for all three vPMs.
Results of the Q test and Higgins I² confirm substantial heterogeneity for all cohorts.
Together, the Cochran Q test of homogeneity (p = < 0.0001) with Higgins I² (> 50%), which
quantifies the degree of heterogeneity, determined the studies were not homogeneous. The
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results showed true heterogeneity between studies for APACHE II (I² = 94.56%), SAPS II (I² =
94.66%), and SOFA (I² = 80.21%). These finding were expected because the studies were not
from a common population.
Table 5.
Test of Heterogeneity

*Q is the weighted sum of squares on a standardized scale. It is reported with a p value with
2
low P-values indicating presence of heterogeneity. I is the percentage of observed total
variation across studies that is due to real heterogeneity rather than chance. It is calculated
2
as I = 100% x (Q - df)/Q. A value of 0% indicates no observed heterogeneity and larger
values show increasing heterogeneity.
A meta-regression requires weight be assigned to each pooled study. Cochran’s Q is the
weighted sum of squares and reflects the total dispersion of studies around the grand mean. Each
Q statistic was evaluated with respect to its degrees of freedom and the weighted pooled studies
are graphed in forest plots (Figures 5, 6 and 7). To the left of each forest are the studies reporting
the AUC for the respective cohort group. The studies are listed alphabetically and repeated when
2 or more AUCs are reported in its outcomes. Each study is represented by a filled square to
denote its AUC and the horizontal line signifies the corresponding 95% confidence interval. The
diamond at the bottom of each graph is the pooled estimated mean performance and width
reflects the precision of that estimate based on random-effects modeling.
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AUC = .804 [95% CI 0.763 –
0.845]
Estimated performance
mean

Figure 5. APACHE II Cohort: Pooled Weighted Studies
Liborio et al. (2011) prospective study (n = 288, hematological/solid cancer) with oncology only
MSICU patient mix performed best in the APACHE II cohort with AUC 0.940. Sculier et al.
(2000) had the worst performing study (n = 261, hematological/solid cancer) with oncology only
MSICU patient mix reporting an AUC of 0.60.The overall pooled magnitude of weighted effect
in this cohort was 0.804 (95% CI 0.763-0.845).
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AUC = .797 [95% CI 0.766
– 0.828]
Estimated performance
mean

Figure 6. SAPS II Cohort: Pooled Weighted Studies
Soares et al. (2004) prospective study (n = 1,257 patients with hematological/solid cancers) in a
MSICU performed best in the SAPS II cohort with AUC 0.916. Sculier et al. (2000) prospective
study had the worst performing outcome (n = 261, hematological/solid cancer) for SAPS II with
oncology only MSICU patient mix reporting an AUC of 0.67.The overall pooled magnitude of
weighted effect in this cohort was 0.797 (95% CI 0.763-0.845).
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AUC = .794 [95% CI 0.749 –
0.839]
Estimated performance
mean

Figure 7. SOFA Cohort: Pooled Weighted Studies
Liborio et al. (2011), prospective study (n = 288 patients with hematological/solid cancers) in a
MSICU performed best in the SOFA cohort with AUC 0.910 while the overall pooled magnitude
of effect in this cohort is 0.794 (95% CI 0.749 – 0.839). Greenberg et al. (2016) had the worst
performing study (n = 245, hematology cancers) with an AUC of 0.65 that was conducted
retrospectively in a MICU. This model was being compared to a development model in the
primary study.
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The pooled or summary AUCs for APACHE II, SAPS, and SOFA were 0.804, 0.797, and 0.794, respectively (see Table 6).
The APACHE II demonstrated good discrimination while SAPS II and SOFA showed fair discrimination. The fixed-effect model was
invalid because heterogeneity was significant for all three vPMs and confirmed why random-effects modeling was selected (see Table
5). The random-effects AUCs were then compared (APACHE II with SAPS II, p = 0.7897, APACHE II with SOFA p = 0.7471, SAPS
II with SOFA p = 0.9147) for all models. The findings led to the statistical conclusion that the performances of AUCs for the three
cohorts are not significantly different; therefore, the weighted performance means are similar.
Table. 6.
Summary AUC with Random-Effects Model

The pooled Area under the ROC curve with 95% CI is given both for the Fixed effects model and the Random
effects model.
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Accounting for Bias
Publication bias is a threat to the validity of clinical research, which can distort the
totality of the available evidence on a research question. This can lead to misleading inferences
in systematic reviews and meta-analyses (Haidich, 2010). The Egger’s test was performed to
detect publication biases (e.g., only publishing studies with favorable outcomes), which were
depicted graphically using funnel plots. There are more than 10 articles with statistically
significant findings in each study included in this meta-regression, making it appropriate for
testing (Egger et al., 1997; Sterne & Egger, 2001).
Funnel plots are displayed below for each cohort of vPM studies (Figures 8, 9, and 10).
The unfilled circles are plotted according to the reported AUCs (x-axis) and corresponding SEs
(y-axis). Two diagonal lines represent (pseudo) 95% confidence limits (effect ± 1.96 SE) around
the summary effect for each standard error on the vertical axis. If publication bias is present, the
funnel plot will be asymmetrical.
Both APACHE II (Figure 8) and SAPS II (Figure 9) cohorts showed symmetry. The
SOFA cohort (Figure 10) was expected to be vulnerable to bias due to the smaller number of
studies (low statistical power) included in this model cohort. It is asymmetrical because the
majority of the AUCs are not evenly dispersed in the funnel; rather, they collected to the left of
0.8 median. Low statistical power in the presence of heterogeneity can lead to false claims of
publication bias (Loannidis & Trikalinos, 2007). The SOFA cohort was asymmetrical implying
publication bias. However, smaller number of studies (n = < 10) tend to show larger effects that
mimic bias and reduced heterogeneity may be exaggerated by the small sample size.
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Symmetrical plot

Figure 8. APACHE II Funnel Plot Asymmetry Test

62

Symmetrical plot

Figure 9. SAPS II Funnel Plot Asymmetry Test
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Asymmetrical plot

Figure 10. SOFA Funnel Plot Asymmetry Test

Independent Predictors of Mortality
The secondary aim of the study was to identify independent predictors of mortality
measured and reported in the 22 eligible validation studies. Physiological variables of interest
were limited to physiological covariates in which univariate analyses were performed to detect a
statistically significant (p < 0.05) influence on ICU mortality. The intent was to identify and
describe physiological variables not captured in vPM algorithms and were associated with 30day ICU mortality risk.
Physiological variables identified as independent predictors, but already measured in a
model, were not included in data extraction. As a result, the inquiry yielded no results. For
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example, Benoit et al. (2003) identified requiring intubation within the first 24 hours of
admission, serum creatinine > 1.2, and blood urea nitrogen > 0.75, leucopenia, and the use of
vasopressors as prognostic indicators of 30-day ICU mortality. These variables are already
measured in the vPMs; therefore, offer no meaningful insights for this type research question.
The most frequently occurring independent prognostic indicator of mortality risk was the use of
vasopressors, which is measured in the SOFA model.
In the Soares et al. (2004) study (n =1,257), APACHE II (AUC 0.89) and SAPS II (0.92)
showed good to excellent discrimination without independent prognostic variables explored in
the analysis. The Liborio et al. (2011) study (n = 288) also showed good (SAPS II, AUC 0.869)
and excellent (APACHE II, AUC 0.940; SOFA, AUC 0.910) discrimination. In this study, the
authors identified 13 physiological variables that increased risk for hospital mortality but the
models also address these predictors. After surveying the articles, there was insufficient data to
analyze, summarize, or describe independent predictors associated with 30-day ICU mortality
not captured in the vPMs.
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Chapter 5
Summary
The approach chosen to determine the vPM most suitable for the critically ill cancer
population was a meta-analysis using meta-regression with random-effects modeling technique.
Study-level data were extracted from prospective and retrospective cohort-type validation studies
aimed at the predictive accuracy of APACHE II, SAPS II, and SOFA models. After applying
PRISMA criteria to the literature search, 22 articles met eligibility criteria. The CHARMS
protocol guided data extraction. Together, PRISMA criteria and CHARMS protocol was a
structured approach to organizing the steps to answering the research questions and reporting the
outcomes.
Systematically reviewing the literature provided a sufficient amount of data to generate
diagnostic performance statistics. The processed yielded 32,303 combined predictions performed
among the three vPMs. The APACHE II, SAPS II, and SOFA cohort groups performed a total of
16,764, 12,960, and 2,579 mortality predictions respectively. Predictive accuracy for APACHE
II ranged from 0.60 to 0.94 (0.800), SAPS II 0.67 to 0.92 (0.792), and SOFA 0.68 to 0.91 (0.794)
across the 22 validation studies.
Random-effects accounted for between-study variance and heterogeneity, resulting in a
weighted mean for individual studies and pooled mean effects. Study weights led to APACHE II
cohort performance mean increasing slightly to 0.804 from the 0.800 after accounting for
heterogeneity. The SAPS II cohort performance mean increased to 0.797 when compared to the
0.792 before random-effects modeling. The SOFA cohort improved most with an initial 0.785
that changed to 0.794 performance mean effect. The conclusion is APACHE II demonstrated
good discrimination while SAPS II and SOFA showed fair discrimination.
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The overall performance means for APACHE II, SAPS, and SOFA were 0.804, 0.797,
and 0.794, respectively. Based on the findings, the APACHE II demonstrated greatest predictive
accuracy when compared to SAPS II and SOFA models. Although APACHE II performed best,
clinical significance is not established based on these findings. Measures of correlation among
vPMs demonstrated no relationships between the models. Adjunct to vPM research, no
independent predictors of to 30-ICU mortality were identified in this study.
Discussion
Diversity among researchers tends to lead toward different approaches to investigating
important questions. In this study, examining previous works centered on questions about the
performances of vPMs in the ICU wasdeemed important to delivering quality bedside care. The
varying approaches to uncovering the answer to vPM performances created an opportunity to
integrate the findings from multiple independent studies to inform evidence-based practice.
Similarities in methodologies and aims centered on the vPM performances in the critically ill
oncology population resulted in independent studies being aggregated using statistical
procedures to quantify significance to bedside care.
Sample
Following PRISMA guidelines, this study was a systematic attempt at quantifying the
results of independent research to gain evidence-based knowledge that will further guide clinical
practice. A limitation of this approach is study-level data. In contrast to data at the subject-level,
study level data is restricted to information available for extracting from independent reporting
of findings. Issues such as individual study bias, design flaws, and improper data collection
techniques cannot be managed using the methodological approach in this study. Nevertheless,
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the random-effects models accounted for heterogeneity associated with differences in
characteristics of studies and study populations.
The CHARMS protocol added scientific rigor because it pre-specified the objectives and
methods of data extraction. The study sample was limited to validation studies that were testing
vPMs performances in new populations (i.e., oncology patients) to determine if clinical validity
was maintained in specific patient groups. A strong point of this approach is the ability to isolate
the performances in a group for analysis. The limitation of this approach was the lack of model
performance comparisons with performances in general ICU populations. Whether or not the
models perform better in the general population remains unknown.
Following the CHARMS protocol restricted post hoc decisions during the review
process; thus limiting bias such as selective outcome reporting. Publication bias is a concern for
publishing only studies that demonstrate favorable outcomes. The Egger’s test showed no
publication bias associated with the APACHE II and SAPS II cohorts. The AUC performances in
each group varied: 0.60 to 0.94 (APACHE II), 0.67 to 0.92 (SAPS II), and 0.68 to 0.91 (SOFA).
The APACHE II cohort demonstrated the widest range gap (0.34) and SOFA had the narrowest
range gap (0.23). The small sample of studies identified for the SOFA model can be attributed
low statistical power and reduced heterogeneity.
Primary Study Aim
A validated prognostic model performance is related directly to the ratio between
accurate predictions and observed outcomes when establishing legitimacy for bedside
application. In this study, APACHE II performed with greatest accuracy but had significantly
more predictions in comparison with the other models. It is the gold standard among vPMs,
which can be attributed to the availability of more studies and greater reporting of prediction
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events. The least performing vPM, SOFA, had significantly fewer predictions because of fewer
published studies available for statistical analysis. The SAPS II model’s overall performance was
closer to APACHE II, which coincided with a comparable number of prediction events.
The strength of using meta-regression to summarize the findings of multiple studies is its
scientific approach. It objectively reduces conflict and ambiguity associated with examining the
evidence based solely on case-by-case analysis. A key limitation is the grouping of performance
assessed based on study-level data. In this study, the data is based on model overall performance
(i.e., mean) as reported in individual studies rather than scrutiny of performance at the individual
level. Predictive accuracy cannot be stratified using study-level data.
Individual level data is more appropriate for observing performance differences
representative of physiological extremes and gray areas. For example, a vPM performance
among terminally ill patient populations is probably greater than 0.9 (i.e., excellent
discrimination). Likewise, vPM performance for patients admitted for low acuity needs such as
observation status is also favorable towards high predictive accuracy. Evidence supporting the
validity of vPMs are important to the bedside nurse and physician. However, research of
prognostic models outcomes among cancer patients with clinically ambiguous situations may be
more meaningful. As a result, predictions that are objective for oncology patients who fall in the
uncertainty category still need to be addressed in future research.
Secondary Study Aim
The secondary aim of the study was the identification of independent predictors of ICU
mortality not included in APACHE II, SAPS II, and SOFA models. The impetus for this
exploration was to gain new insights into routinely measured physiological variables that may
improve the predictive performance of any widely accepted vPM. Identifying independent

69

predictors of mortality are important to clinical nursing because early warning signs are a part of
critical thinking and anticipatory care in nursing practice. After surveying the articles, there was
insufficient data to analyze, summarize, or describe independent predictors associated with 30day ICU mortality not captured in the models.
Ongoing investigation is required to determine independent predictors of mortality, not
measured in the models. Restricting the search of independent predictors to reporting along with
model performances was a limitation of this study. Conducting a meta-analysis of independent
predictors may better address the secondary aim. This is more salient when examined in the
context of the primary findings. That is to say, the main effects of vPMs in this study ranged
from fair to good discrimination (0.0794 – 0.804). Identifying covariates that better capture the
unique physiological challenges associated with cancer and its related treatment must be
investigated to determine if the overall performance of model predictions can be improved to >
0.90 in this population.
Conclusion
As the gold standard among vPMs, APACHE II performed with greatest predictive
accuracy and achieved good discrimination (> 0.80). Its combination of physiological variables,
prediction algorithm and objectivity remained valid after scrutiny in this study. Heterogeneity
was established across studies with no publication bias observed. Because the outcome is based
on study-level data, ongoing research is need to explore the clinical significance and practical
application of APACHE II in the critically ill oncology ICU sub-population. Pursuing clinical
significance is an opportunity to examine feasibility, impact of use on staff attitudes, and
application to decision-making at the bedside.
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The overall performance was 0.804 for APACHE II. Nevertheless, a model that predicts
at 0.9 or better (excellent discrimination) would be ideal. Because the model has not reached its
full potential, the identification of additional physiological variables associated with ICU
mortality using a different approach is warranted. In effect, identifying physiological variables
most predictive of outcomes in the oncology patient will lead to the need to update current
models. This includes adding variables representative of homeostasis, modifying algorithms, and
ensuring that model changes improve performance and maintain objectivity.
Although SAPS II and SOFA did not perform as well, improving performance remains an
important contribution to critical care management. A contributing factor to SOFA performance
may be due to it being under-investigated in the cancer population. Cancer is one of the leading
causes of death worldwide, but the overall number of articles retrieved was small relative to
disease impact. Having a small number of studies to review was a limitation of conducting metaanalysis to answer both research questions. Limited information to support evidence-based
practice supports continued nurse-led investigations centered on prognosis-related research.
Nursing Implications
The utility of prognostic models relies on capturing and documenting the physiological
variables observed by CCNs during hemodynamic monitoring. These physiological variables
function as prognostic factors by which the intensivists use the information to formulate a
realistic clinical picture in collaboration with the bedside nurse. Together, the CCNs and
intensivists use their expertise and practice scopes to demonstrate their collective investment in
the well-being of the patient and assurance of delivering evidence-based, quality care. Therefore,
future research should be centered on how prognostic information is shared at the bedside.
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Prognosis research is central to addressing these types of issues in the clinical setting.
Nurse-led research should focus on the contextual meaning of prognosis to the nurse and patient.
Understanding its meaning will help CCNs better function as advocates during the decisionmaking process. Nursing investigation exploring vPM use as decision support aids have the
potential to be far reaching. Particularly, nursing investigation should focus on the ICU setting
because admission to the ICU is associated with anxiety and fears experienced among patients
and family members; while nurses and physicians have concerns about delivering futile care.
Shared decision-making is a process and model use has implications for helping to reduce
uncertainty experienced by patients, nurses, and physicians during a most critical time. Because
prognosis involves two-way conversations, careful consideration for how vPMs are introduced
into communication exchanges is important to advance nursing science. Explanations of
prognoses should be undergirded by rich information delivered in a systematic, impartial, yet
empathetic fashion but gaps in the literature exist about the role of nursing. This gap creates an
opportunity for nurse-led investigation related to prognosis and nursing advocacy, education, and
policy.
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Appendix A. Combination ICU Mortality Model
Use the worst value (US units) for each physiological variable within the past 24 hours.
VITALS
HR

BP

RR

Temp

GCS

/
bpm

bpm

mmHg

C or F

ARTERIAL BLOOD GAS
pH

pCO2

pO2

mmHg

FiO2

%

mmHg

Yes

Mechanical ventilation or CPAP

No

CHEM-7
Na

K

CO2

mEq/L

mEq/L

mEq/L

Acute renal failure

BUN

SCr

mg/dL

mg/dL

Yes

No

Combination of APACHE II, SAPS II, and SOFA models to predict hospital mortality.
Publically available at http://clincalc.com/IcuMortality/Default.aspx
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Appendix A. Combination ICU Mortality Model (continued)
CBC
WBC

Hct

x 109/L

Plt

%

x103/mm3

MISC METRICS
Urine output

mL

Bilirubin

per hour

mg/dL

Vasopressors

No

Yes

CHRONIC HEALTH
Age

years
Metastatic cancer

Chronic diseases

Hematologic malignancy
AIDS

Type of admission
Does this patient have severe organ system
insufficiency or is immunocompromised? See
definitions
Reset

Scheduled (elective) surgical

No

Yes

Calculate

Combination of APACHE II, SAPS II, and SOFA models to predict hospital mortality.
Publically available at http://clincalc.com/IcuMortality/Default.aspx
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Appendix B. Acute Physiology and Chronic Health Evaluation II
Use the worst value (US units) for each physiological variable within the past 24 hours.
Age

years

Glasgow coma score
Vitals
Temp

C or F

MAP

mmHg

Heart rate

bpm

Resp rate

bpm
Oxygenation

FiO2

%

PaO2

mmHg

Arterial pH
Chemistry
Sodium

mEq/L

Potassium

mEq/L

Creatinine

mg/dL

Acute renal failure

No

Yes

Hematology
Hematocrit

%

WBC

x 109/L

Severe organ system insufficiency or is
immunocompromised

No
Reset

Yes

Calculate

APACHE II model to predict 30-day ICU mortality. Publically available at
http://clincalc.com/IcuMortality/APACHEII.aspx
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Appendix C. Simplified Acute Physiology Score II
Age

years
Vitals

Heart rate

bpm

Systolic BP

mmHg

Temp

C or F

Glasgow coma score
Oxygenation
Yes

Mechanical ventilation or CPAP
PaO2

No
mmHg

FiO2

%
Renal

Urine output

mL

BUN

per hour

mg/dL

Chemistry
Sodium

mEq/L

Potassium

mEq/L

Bicarbonate

mEq/L

Bilirubin

mg/dL

Other
WBC

x 109/L
Metastatic cancer

Chronic diseases

Hematologic malignancy
AIDS

Scheduled surgical
Type of admission
SAPS II model to predict 30-day ICU mortality. Publically available at
http://clincalc.com/IcuMortality/APACHEII.aspx
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Appendix C. Simplified Acute Physiology Score II (continued)
Use the worst value (US units) for each physiological variable within the past 24 hours.
Reset

Calculate

SAPS II model to predict 30-day ICU mortality. Publically available at
http://clincalc.com/IcuMortality/APACHEII.aspx
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Appendix D. Sequential Organ Failure Assessment
Use the worst value (US units) for each physiological variable within the past 24 hours.
Respiration
FiO2

%

PaO2

mmHg

Mechanical ventilation

No

Yes

Coagulation
Platelets

x103/mm3
Liver

Bilirubin

mg/dL

Neurological
Glasgow coma score
Cardiovascular
MAP

mmHg

Vasopressors

No

Yes

Renal
Creatinine
Urine output

mg/dL
Greater than 500 mL/day

Reset

Calculate

SOFA model to predict 30-day ICU mortality. Publically available at
http://clincalc.com/IcuMortality/SOFA.aspx
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Appendix E. Overall Predictive Performance of Prognostic Models in the Literature
Study

1.Benoit,
et al (2003)

Prognostic
Model
(validation
groups only)
APACHE II

AUC

Standard Error
(SE)

95% Confidence
Interval

HosmerLemeshow
goodness-of-fit
p value

0.71

0.043

NP*

0.39

0.77

0.043

NP

0.6

0.72

0.045

NP

< 0.001

0.65

0.047

NP

0.002

0.79

0.083

0.62 – 0.95

NP

0.85

0.056

0.75 – 0.96

NP

0.79

0.024

0.74 – 0.83

0.87

0.79

0.063

0.63 – 0.94

0.01

0.77

0.061

0.65 – 0.90

NP

0.70

0.068

0.56 – 0.84

NP

0.83

0.064

NP

0.98

0.78

0.070

NP

0.49

0.87

0.021

0.83 – 0.91

0.13

SAPS II
2. Berghmans,
et al (2004)

SAPS II
APACHE II

3. Can,
et al (2008)

APACHE II
SAPS II

4. Cardenas-Turanzas,
et al (2012)

SOFA ¹
SOFA ²

5. Cornet,
et al (2005)

SOFA
SAPS II

6. Ertan,
et al (2008)

SAPS II
APACHE II

7. Fang,
et al (2014)

APACHE II ³
APACHE II ⁴

0.83
0.043
0.75 – 0.91
0.13
¹Validation cohort, n = 540 medical patient group; ² Validation cohort, n = 783 surgical patient group; ³ Validation cohort, n =
851 patients; ⁴ Validation cohort, n = 665 patients; *NP – Not provided
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8. Greenberg,
et al (2016)

Prognostic
Model
(validation
groups only)
SOFA ⁵

AUC

Standard Error
(SE)

95% Confidence
Interval

HosmerLemeshow
goodness-of-fit
p value

0.68

0.038

0.61 – 0.76

0.25

0.65

0.039

0.58 – 0.73

0.31

0.74

0.006

0.73 – 0.76

< 0.001

0.74

0.006

0.73 – 0.75

< 0.001

0.90

0.030

0.84 – 0.95

0.17

0.83

0.040

0.75 – 0.89

0.22

0.87
0.78
0.79
0.78
0.79

0.030
0.048
0.047
0.048
0.047

0.80 – 0.93
0.69 – 0.88
0.69 – 0.89
0.69 – 0.88
0.68 – 0.89

0.14
0.92
0.92
0.32
0.32

0.94

0.016

0.92 – 0.97

0.24

0.87

0.023

0.83 – 0.91

0.24

0.91

0.020

0.88 – 0.94

0.24

APACHE II ⁶
9. Hampshire,
et al (2009)

APACHE II
SAPS II

10. Kopterides,
et al (2011)

APACHE II
SAPS II
SOFA

11. Lamia,
et al (2006)

12. Liborio,
et al (2011)

SAPS II ⁷
SAPS II ⁸
SOFA⁷
SOFA⁸
APACHE II
SAPS II
SOFA

13. Merz,
et al (2008)

SAPS II

0.80
0.060
0.70 – 0.90
Og**
0.69
0.067
0.57 – 0.80
Og
SOFA
⁵ ⁶ Validation cohort, n = 196 patients; ⁷ Validation cohort, n = 92 patients; ⁸ Validation cohort, n = 81 excluding allogenic
Hematopoietic Stem Cell Transplantation patients.
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14. Namendys-Silva,
et al (2010)
15. Namendys-Silva,
et al (2012)

Prognostic
Model
(validation
groups only)
APACHE II

AUC

Standard Error
(SE)

95% Confidence
Interval

HosmerLemeshow
goodness-of-fit
p value

0.92

0.031

0.88 – 0.96

0.25

0.83

0.088

0.73 – 0.95

0.62

0.87

0.031

0.88 – 0.96

0.25

0.73

0.034

0.66 – 0.80

NP

0.78

0.032

0.71 – 0.86

NP

0.78

0.036

0.71 – 0.83

0.06

0.83

0.027

0.77 – 0.88

0.07

0.60

0.038

NP

< 0.001

0.67

0.037

NP

< 0.001

0.89

0.010

0.87 – 0.91

< 0.001

0.75

0.021

0.71 – 0.79

< 0.001

0.92

0.009

0.90 – 0.93

< 0.001

0.82

0.018

0.78 – 0.85

< 0.001

0.84

0.021

0.81 – 0.87

0.007

APACHE II
APACHE II

16. Pohlen,
et al (2016)

SAPS II
SOFA

17. Schellongowski,
et al (2004)

APACHE II ⁹
SAPS II ⁹

18. Sculier,
et at (2000)

APACHE II
SAPS II

19. Soares,
et al (2004)

APACHE II ¹⁰
APACHE II ¹¹
SAPS II ¹⁰
SAPS II ¹¹

20. Soares,
et al (2010)

SAPS II ¹²
SAPS II ¹³

0.77
0.026
0.72 – 0.82
0.94
⁹ Validation cohort, n = 242 medical cancer patients; ¹⁰ Validation cohort, n = 1257 including scheduled surgery patients; ¹¹
Validation cohort, n = 542 medical and emergency surgical patients only.
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Study (continued…)

21. Xing,
et al (2015)

Prognostic
Model
(validation
groups only)
APACHE II ¹⁴

AUC

Standard Error
(SE)

95% Confidence
Interval

HosmerLemeshow
goodness-of-fit
p value

0.86

0.036

0.804 – 0.923

0.900

0.87

0.069

0.774 – 0.958

0.594

0.83

0.045

0.757 – 0.911

0.594

0.78

0.029

0.72 – 0.83

NP

APACHE II ¹⁵
APACHE II ¹⁶
22. Yan,
et al (2012)

APACHE II

¹Validation cohort, n = 540 medical patient group; ² Validation cohort, n = 783 surgical patient group; ³ Validation cohort, n = 851 patients; ⁴
Validation cohort, n = 665 patients; ⁵ˏ⁶ Validation cohort, n = 196 patients; ⁷ Validation cohort, n = 92 patients; ⁸ Validation cohort, n = 81
excluding allogenic Hematopoietic Stem Cell Transplantation patients; ⁹ Validation cohort, n = 242 medical cancer patients; ¹⁰ Validation
cohort, n = 1257 including scheduled surgery patients; ¹¹ Validation cohort, n = 542 medical and emergency surgical patients only; ¹²
Validation cohort, n = 717 patients; ¹³ Validation cohort, n = 336 without scheduled surgical patients; ¹⁴ Validation cohort n = 981; ¹⁵
Validation cohort, n = 70, non-scheduled surgery patients; ¹⁶ Validation cohort, n = 911, scheduled surgery patients; *NP – Not provided; **
Og = other goodness-of-fit test performed; *** NI = not indicated.
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Appendix F. Characteristics of the Validated Studies Included in Meta-Regression
Study

Country

Location(s)

Study
Period

Setting(s)

Sample
Size

Cancer Type

Study Type

Solid &
hematologic
malignancy
Solid &
hematologic
malignancy
Colorectal
cancer (surgical
resection)

Retrospective
cohort study

EVꭞ

SPSS 9.0

Prospective cohort
study

EV

Not
indicated

Prospective cohort
study

EV

SPSS 11.0

Hematologic
and solid
malignancy

Cross-Validation,
Retrospective
cohort study

(# of
patients)

Benoit,
et al (2003)

Belgium

1 university
hospital

Jan 1997 to
June 2000

Adult
MICU*

146

Berghmans,
et al (2004)

Belgium

Jan 1999 to
June 2000

Adult**
MICU-O

247

Can,
et al (2008)

Turkey

1 oncology
specialty
hospital
1 tertiary
community
hospital

Not
indicated

224

CardenasTuranzas,
et al (2012)

USA

Sept
2003 to
March
2006
Jan 2006 to
Dec 2008

Adult***
MSICU

6645

Cornet,
et al (2005)

Netherlands

Ertan,
et al (2008)
Fang,
et al (2014)

Turkey

Greenberg,
et al (2016)

USA

Hampshire,
et al (2009)

China

United
Kingdom

1 universityaffiliated,
oncology
specialty
hospital
1 university
hospital

Type of
prediction
modeling

PMꭞ

Statistical
Software

ꭞ

PASW 17.0

(n = 2069, medical) +
(n = 3253, surgical)

with EV
(n = 540) +
(n = 783, surgical)

Nov 1995
to Dec
2002

Adult
MICU

58

1 university
hospital
1 tertiary
community
hospital
1 universityaffiliated
hospital

Jan 1998 to
July 2004
1991 –
2011

Not
indicated
Adult*ꭞ
ICU-NS

102

Sept 2009
to Sept
2014

Adult
MICU

246

178
hospitals

Dec 1995
to March

Adult
MSICU

851

Acute Myeloid
Leukemia and
non-Hodgkin
lymphoma
Colorectal
cancer
Gastric cancer
(surgical
resection)
Hematologic
malignancy

Retrospective
cohort study with
prospective
follow-up
Retrospective
cohort study
Retrospective
cohort study
Retrospective
cohort study

EV

Not
indicated

EV

Not
indicated
STATA
11.0

EV

PM
(n = 50) with EV

STATA
13.1

(n = 196)

7,689

128

Solid &
hematologic

Retrospective
cohort study

EV

STATA 9.2

Kopterides,
et al (2011)

Greece

Lamia,
et al (2006)

France

Liborio,
et al (2011)

Brazil

Merz,
et al (2008)

Switzerland

NamendysSilva,
et al (2010)
NamendysSilva,
et al (2012)
Pohlen,
et al (2016)

Mexico

Mexico

Germany

Schellongowski
et al (2004)

Austria

Sculier,
et at (2000)

Belgium

Soares,
et al (2004)

Brazil

malignancy
Solid &
hematologic
malignancy

Prospective
observational
study

EV

SPSS 10.0
& MedCalc
16.6

92

Hematologic
malignancy

Retrospective
cohort study

EV

STATA 8.0

Adult**ꭞ
MSICU-O

288

SPSS 17.0

101

Prospective
observational
study
Retrospective
cohort study

EV

Adult
MSICU

Solid &
hematologic
malignancy
Hematologic
malignancy

EV

SPSS 13.0

Adult
MSICU-O

117

Solid
malignancy

EV

SPSS 15.0

Jan 2007 to
Oct 2007

Adult
MSICU-O

52

Gynecological
cancer

EV

SPSS 15.0

Nov 2004
to Sept
2011

Adult
ICU-NS

451

Acute Myeloid
Leukemia

Prospective
observational
study
Prospective
observational
study
Cross-Validation,
Retrospective
cohort study

PM
with

SPSS 22.0

1 university
oncology
specialty
hospital
1 oncology
specialty
hospital

March
1998 and
July 2002

Adult
MSICU

1 oncology
specialty
hospital

1 university
hospital & 1
tertiary
hospital
1 university
hospital
1 oncology
specialty
hospital
1 university
hospital
1 oncology
specialty
hospital
1 oncology
specialty
hospital
3 universityaffiliated,
hospitals

2007
Jan 2005 to
Dec 2007

Adult
MSICU

126

Jan 2000 to
July
2003
May 2006
to June
2008
July 2001
to July
2005
Jan 2007 to
Oct 2007

Adult
MICU

(n = 187)

EV (n = 264)

242

Solid &
hematologic
malignancy

Prospective
cohort study

EV

SAS

Oct 1992 to Adult
Aug 1995
MICU-O

261

Solid &
hematologic
malignancy

Prospective
cohort study

EV

Not
indicated

May 2000
to July
2003

1972

Solid &
hematologic
malignancy

Prospective
observational
study

EV

SPSS 10.0

Adult
MSICU-O
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Study

Country

Location(s)

Study
Period

Setting(s)

Sample
Size

Cancer Type

Study Type

Type of prediction
modeling

Statistical
Software

717

Solid &
hematologic
malignancy

Prospective
multi-center
cohort study

EV

Not
indicated

(# of
patients)

Soares,
et al (2010)

Brazil

28 Hospitals

Aug 2007
to Sept 30,
2007

Adult
MSICU
(n = 23) &
Adult
MSICU-O
(n = 5)

Xing,
et al (2015)

China

Oct 2008 to Adult
Sept
MSICU
2010

981

Solid
malignancy

Retrospective
cohort study

EV

SPSS 16.0

Yan,
et al (2012)

China

1 universityaffiliated,
oncology
specialty
hospital
2 universityaffiliated,
hospitals

Jan 2005 to
Dec 2009

1695

Colorectal
cancer (surgical
resection)

Retrospective
Cohort study

EV

SPSS 19.0

Adult
ICU-NS

*Adult MICU = Adult Medical Intensive Care Unit; **Adult MICU-O = Adult Oncology Medical Intensive Care Unit; ***Adult MSICU = Adult Medical and Surgical Intensive
Care Unit; *ꭞ Adult ICU-NS = Adult Intensive Care Unit – Not Specified; ** ꭞAdult MSICU-O = Adult Oncology Medical and Surgical Intensive Care Unit; ꭞ External validation =
to assess and compare the predictive performance of an existing prediction model using new participant data; ꭞ ꭞ Prediction model = the development of the model is followed by
quantifying the model’s predictive performance in participant data external to the development dataset.
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OBJECTIVE
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